Document:

EX-10.2

 Exhibit 10.2 

CARBYLAN THERAPEUTICS, INC. 

2014 STOCK OPTION PLAN 

1.  Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel
for positions of substantial responsibility, to provide additional incentive to Employees, Directors and Consultants and to promote the success of the Company’s business by providing for the grant of Incentive Stock Options and Nonstatutory
Stock Options. 
 2.  Definitions. As used herein, the following definitions shall apply: 

(a) “Administrator” means the Board or any of its Committees as shall be administering the Plan in
accordance with Section 4 hereof. 
 (b) “Applicable Laws” means the requirements relating to the
issuance of stock, the administration of stock plans, the taxation of stock awards, and corporate governance under U.S. state corporate laws, U.S. federal and state securities laws, the Code, any stock exchange or quotation system on which the
Common Stock is listed or quoted and the applicable laws of any other country or jurisdiction where Awards are granted under the Plan. 

(c) “Award” means an award of an Option or Restricted Stock held pursuant to the exercise of an Option. 

(d) “Board” means the Board of Directors of the Company. 

(e) “Change in Control” means the occurrence of any of the following events: 

(i)       Any “person” (as such term is used in Sections 13(d) and 14(d) of the
Exchange Act) becomes the “beneficial owner” (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the
Company’s then outstanding voting securities, except that any change in the beneficial ownership of the securities of the Company as a result of a private financing of the Company that is approved by the Board, shall not be deemed to be a
Change in Control; or 
 (ii)       The consummation of the sale or disposition by the
Company of all or substantially all of the Company’s assets; or 
 (iii)       The
consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent
(either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving
entity or its parent outstanding immediately after such merger or consolidation. 

 (f) “Code” means the Internal Revenue Code of 1986, as amended.
Any reference to a section of the Code herein will be a reference to any successor or amended section of the Code. 
 (g)
“Committee” means a committee of Directors or of other individuals satisfying Applicable Laws appointed by the Board in accordance with Section 4 hereof. 

(h) “Common Stock” means the Common Stock of the Company, par value $0.001 per share. 

(i) “Company” means Carbylan Therepeutics, Inc., a Delaware corporation. 

(j) “Consultant” means any person who is engaged by the Company or any Parent or Subsidiary to render
consulting or advisory services to such entity. 
 (k) “Director” means a member of the Board. 

(l) “Disability” means permanent and total disability as defined in Section 22(e)(3) of the Code. 

(m) “Employee” means any person, including officers and Directors, employed by the Company or any Parent or
Subsidiary of the Company. Neither service as a Director nor payment of a director’s fee by the Company shall be sufficient alone to constitute “employment” by the Company. 

(n) “Exchange Act” means the Securities Exchange Act of 1934, as amended. 

(o) “Exchange Program” means a program under which (a) outstanding Options are surrendered or cancelled
in exchange for Options of the same type (which may have lower exercise prices and different terms), Options of a different type, and/or cash, and/or (b) the exercise price of an outstanding Option is reduced, in either case, other than in
connection with a “corporate transaction” as defined in Section 1.424-1(a)(3) of the Treasury Regulations. The terms and conditions of any Exchange Program will be determined by the Administrator in its sole discretion, provided that
any new exercise price will not be lower than the Fair Market Value of a Share on the date of the exchange. 
 (p)
“Fair Market Value” means, as of any date, the value of Common Stock determined as follows: 

(i)       If the Common Stock is listed on any established stock exchange or a national market
system, including without limitation the Nasdaq National Market or The Nasdaq SmallCap Market of The Nasdaq Stock Market, its Fair Market Value shall be the closing sales price for such stock (or the closing bid, if no sales were reported) as quoted
on such exchange or system on the day of determination, as reported in The Wall Street Journal or such other source as the Administrator deems reliable; 

(ii)       If the Common Stock is regularly quoted by a recognized securities dealer but
selling prices are not reported, its Fair Market Value shall be the mean between the high bid and low asked prices for the Common Stock on the day of determination; or 

  
 -2- 

 (iii)       In the absence of an established
market for the Common Stock, the Fair Market Value thereof shall be determined in good faith by the Administrator, consistent with the rules of Sections 409A and 422 of the Code to the extent applicable. 

(q) “Incentive Stock Option” means an Option intended to qualify as an incentive stock option within the
meaning of Section 422 of the Code. 
 (r) “Nonstatutory Stock Option” means an Option not intended
to qualify as an Incentive Stock Option. 
 (s) “Option” means a stock option to purchase Shares granted
pursuant to the Plan. 
 (t) “Option Agreement” means a written or electronic agreement between the
Company and an Optionee evidencing the terms and conditions of an individual Option grant. The Option Agreement is subject to the terms and conditions of the Plan. 

(u) “Optioned Stock” means the Common Stock subject to an Option. 

(v) “Optionee” means the holder of an outstanding Option granted under the Plan. 

(w) “Parent” means a “parent corporation,” whether now or hereafter existing, as defined in
Section 424(e) of the Code. 
 (x) “Plan” means this Carbylan Therapeutics, Inc. 2014 Stock Option
Plan. 
 (y) “Restricted Stock” means restricted Shares issued pursuant to the early exercise of an
Option. 
 (z) “Restricted Stock Purchase Agreement” means a written or electronic agreement between the
Company and the Optionee evidencing the terms and restrictions applying to Restricted Stock purchased pursuant to an Option Agreement that provides for early exercise of Options prior to vesting. The Restricted Stock Purchase Agreement is subject to
the terms and conditions of the Plan and the notice of grant. 
 (aa)      “Service
Provider” means an Employee, Director or Consultant. 

(bb)      “Share” means a share of the Common Stock, as adjusted in accordance
with Section 12 below. 
 (cc)      “Subsidiary” means a
“subsidiary corporation,” whether now or hereafter existing, as defined in Section 424(f) of the Code. 

3.  Stock Subject to the Plan. 

(a) Number of Shares.     Subject to adjustment as provided in Section 12(a) of the Plan, the
maximum aggregate number of Shares that may be delivered in satisfaction of Awards under the Plan is One Million (1,000,000) Shares (and all of which may be delivered upon the exercise of ISOs). The Shares may be authorized but unissued, or
reacquired Common Stock. In 

  
 -3- 

 
addition, any Shares that remain available for issuance under the Carbylan Biosurgery, Inc. Amended and Restated 2004 Stock Option Plan (the “2004 Plan”) upon its
expiration, or that become available for grant under the 2004 Plan following its expiration as a result of the forfeiture of awards granted under the 2004 Plan, will be available for issuance under this Plan. 

(b) Shares Returned to the Plan. If an Award expires or becomes unexercisable without having been exercised in full,
or is surrendered pursuant to an Exchange Program, the unpurchased Shares that were subject thereto shall again become available for future grant or sale under the Plan (unless the Plan has terminated). However, Shares that have actually been issued
under the Plan, upon exercise of an Option or that are withheld by the Company in payment of the exercise price of an Option or in satisfaction of any tax withholding requirements in respect of an Option, shall not be returned to the Plan and shall
not become available for future distribution under the Plan, except that if unvested Shares of Restricted Stock are repurchased by the Company at their original purchase price, such Shares shall become available for future grant under the Plan. 

4.  Administration of the Plan. 

(a) Administrator.     The Plan shall be administered by the Board or a Committee appointed by the
Board, which Committee shall be constituted in accordance with Applicable Laws. 
 (b) Powers of the Administrator.
    Subject to the provisions of the Plan and, in the case of a Committee, the specific duties delegated by the Board to such Committee, and subject to the approval of any relevant authorities, the Administrator shall have the
authority in its discretion: 
 (i)        to determine the Fair Market Value; 

(ii)       to select the Service Providers to whom Options may from time to time be
granted hereunder; 
 (iii)      to determine the number of Shares to be covered by each such
Option granted hereunder; 
 (iv)      to approve forms of agreement for use under the Plan;

 (v)       to determine the terms and conditions of any Award granted hereunder. Such
terms and conditions may include, but are not limited to, the exercise price, the time or times when Options may be exercised (which may be based on performance criteria), any vesting acceleration or waiver of forfeiture restrictions, and any
restriction or limitation regarding any Option or Restricted Stock or Common Stock relating thereto, based in each case on such factors as the Administrator, in its sole discretion, shall determine, regardless of any adverse or potentially adverse
tax or other consequences resulting from such acceleration; 
 (vi)       to institute
an Exchange Program; 
 (vii)      to prescribe, amend and rescind rules and regulations
relating to the Plan, including rules and regulations relating to sub-plans established for the purpose of satisfying applicable foreign laws; 

  
 -4- 

 (viii)    to allow Optionees to satisfy withholding tax
obligations by electing to have the Company withhold from the Shares to be issued upon exercise of an Option that number of Shares having a Fair Market Value equal to the minimum amount required to be withheld. The Fair Market Value of the Shares to
be withheld shall be determined on the date that the amount of tax to be withheld is to be determined. All elections by Optionees to have Shares withheld for this purpose shall be made in such form and under such conditions as the Administrator may
deem necessary or advisable; 
 (ix)      to construe and interpret the terms of the Plan and
Awards granted pursuant to the Plan; and 
 (x)       to otherwise do all things
necessary to carry out the purposes of the Plan. 
 (c) Effect of Administrator’s Decision.
    All decisions, determinations and interpretations of the Administrator shall be final and binding on all Optionees. 

5.  Eligibility. The Administrator will select the Service Providers to whom Options may be granted, provided
that Incentive Stock Options may be granted only to Employees, and further provided that Nonstatutory Stock Options may be granted only to Service Providers who are providing direct services on the date of grant to the Company or a subsidiary of the
Company as described in the first sentence of Section 1.409A-1(b)(5)(iii)(E) of the Treasury Regulations. 

6.    Limitations. 

(a) Incentive Stock Option Limit.     Each Option shall be designated in the Option Agreement as
either an Incentive Stock Option or a Nonstatutory Stock Option. However, notwithstanding such designation, to the extent that the aggregate Fair Market Value of the Shares with respect to which Incentive Stock Options are exercisable for the first
time by the Optionee during any calendar year (under all plans of the Company and any Parent or Subsidiary) exceeds $100,000, such Options shall be treated as Nonstatutory Stock Options. For purposes of this Section 6(a), Incentive Stock
Options shall be taken into account in the order in which they were granted. The Fair Market Value of the Shares shall be determined as of the time the Option with respect to such Shares is granted. 

(b) Rights Limited.     Neither the Plan nor any Award shall confer upon any Award holder any
right with respect to continuing such individual’s relationship as a Service Provider with the Company, nor shall it interfere in any way with his or her right or the Company’s right to terminate such relationship at any time, with or
without cause, and with or without notice. Neither the Plan nor any Award shall confer upon any Award holder any right as a stockholder except as to Shares actually issued under the Plan. The loss of existing or potential profit in Awards will not
constitute an element of damages in the event of termination of relationship as a Service Provider for any reason, even if the termination is in violation of an obligation of the Company or an affiliate to the Service Provider. 

7.  Term of Plan. Subject to stockholder approval in accordance with Section 17, the Plan shall become
effective upon its adoption by the Board. Unless sooner terminated under Section 13, 

  
 -5- 

 
it shall continue in effect for a term of ten (10) years after the earlier of the date of adoption of the Plan and the date the Plan is approved by stockholders. 

8.  Term of Option.     The term of each Option shall be stated in the Option Agreement;
provided, however, that the term shall be no more than ten (10) years from the date of grant thereof. In the case of an Incentive Stock Option granted to an Optionee who, at the time the Option is granted, owns stock representing more than ten
percent (10%) of the voting power of all classes of stock of the Company or any Parent or Subsidiary, the term of the Option shall be five (5) years from the date of grant or such shorter term as may be provided in the Option Agreement.

 9.  Option Exercise Price and Consideration. 

(a) Exercise Price.     The per share exercise price for the Shares to be issued upon exercise of
an Option shall be such price as is determined by the Administrator, but shall be subject to the following: 

(i)        In the case of an Incentive Stock Option 

 (A) granted to an Employee who, at the time of grant of such Option, owns stock representing more than ten percent
(10%) of the voting power of all classes of stock of the Company or any Parent or Subsidiary, the exercise price shall be no less than 110% of the Fair Market Value per Share on the date of grant. 

 (B) granted to any other Employee, the per Share exercise price shall be no less than 100% of the Fair Market Value per
Share on the date of grant. 
 (ii)       In the case of a Nonstatutory Stock Option,
the per Share exercise price shall be determined by the Administrator, having due regard for the requirements for exemption from, or compliance with, Section 409A of the Code. 

(iii)      Notwithstanding the foregoing, Options may be granted with a per Share exercise
price other than as required above in connection with a “corporate transaction” as described in Section 1.424-1(a)(3) of the Treasury Regulations and in accordance with the requirements thereunder. 

(b) Forms of Consideration. The consideration to be paid for the Shares to be issued upon exercise of an Option,
including the method of payment, shall be determined by the Administrator (and, in the case of an Incentive Stock Option, shall be determined at the time of grant). Such consideration may consist of, without limitation, if so permitted by the
Administrator and if legally permissible, (1) cash, (2) check, (3) promissory note, (4) other Shares, provided Shares acquired directly from the Company (x) have been owned by the Optionee, and have not been subject to a
substantial risk of forfeiture, for more than six months on the date of surrender, and (y) that have a Fair Market Value on the date of surrender equal to the aggregate exercise price of the Shares as to which such Option shall be
exercised, (5) consideration received by the Company under a cashless exercise program implemented by the Company in connection with the Plan, or (6) any combination of the foregoing methods of payment. In making its determination as to
the type of consideration to accept, the Administrator shall consider if acceptance of such consideration may be reasonably expected to benefit the Company. 

  
 -6- 

 10. Exercise of Option. 

(a) Procedure for Exercise; Rights as a Stockholder. 

(i)      Any Option granted hereunder shall be exercisable according to the terms hereof at
such times and under such conditions as determined by the Administrator and set forth in the Option Agreement. An Option may not be exercised for a fraction of a Share. 

(ii)  An Option shall be deemed exercised when the Company receives: (i) written or electronic notice of
exercise (in accordance with the Option Agreement) from the person entitled to exercise the Option, and (ii) full payment for the Shares with respect to which the Option is exercised, including any required tax withholding. Full payment may
consist of any consideration and method of payment authorized by the Administrator and permitted by the Option Agreement and the Plan. Shares issued upon exercise of an Option shall be issued in the name of the Optionee or, if requested by the
Optionee, in the name of the Optionee and his or her spouse. Until the Shares are issued (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company), no right to vote or receive dividends
or any other rights as a stockholder shall exist with respect to the Shares, notwithstanding the exercise of the Option. The Company shall issue (or cause to be issued) such Shares promptly after the Option is exercised. No adjustment will be made
for a dividend or other right for which the record date is prior to the date the Shares are issued, except as provided in Section 12 of the Plan. 

(iii)  Exercise of an Option in any manner shall result in a decrease in the number of Shares thereafter available,
both for purposes of the Plan and for sale under the Option, by the number of Shares as to which the Option is exercised. 

(b) Termination of Relationship as a Service Provider. 

(i)        Generally. If an Optionee ceases to be a Service Provider, such Optionee may exercise
his or her Option within such period of time as is specified in the Option Agreement to the extent that the Option is vested on the date of termination (but in no event later than the expiration of the term of the Option as set forth in the Option
Agreement). In the absence of a specified time in the Option Agreement, and except as set forth pursuant to Section 10(b)(ii) or Section 10(b)(iii) below, the vested portion of the Option shall remain exercisable for three (3) months
following the Optionee’s termination. Unless the Administrator provides otherwise, if on the date of termination the Optionee is not vested as to his or her entire Option, the Shares covered by the unvested portion of the Option shall be
forfeited by the Optionee and revert to the Plan. If, after termination, the Optionee does not exercise his or her Option within the time specified herein, the Option shall terminate, and the Shares covered by such Option shall be forfeited by the
Optionee and revert to the Plan. Notwithstanding the foregoing, if the Service Provider is terminated for cause as determined by the Administrator, all Shares covered by the Option, whether vested or unvested, shall immediately be forfeited by the
Optionee and revert to the Plan. 
 (ii)       Disability of Optionee. If an Optionee ceases to be a
Service Provider as a result of the Optionee’s Disability, the Optionee may exercise his or her Option within such period of time as is specified in the Option Agreement to the extent the Option is vested on the date of termination (but in no
event later than the expiration of the term of such Option as set forth in the 

  
 -7- 

 
Option Agreement). In the absence of a specified time in the Option Agreement, the vested portion of the Option shall remain exercisable for twelve (12) months following the Optionee’s
termination. Unless the Administrator provides otherwise, if on the date of termination the Optionee is not vested as to his or her entire Option, the Shares covered by the unvested portion of the Option shall be forfeited by the Optionee and revert
to the Plan. If, after termination, the Optionee does not exercise his or her Option within the time specified herein, the Option shall terminate, and the Shares covered by such Option shall be forfeited by the Optionee and revert to the Plan. 

(iii)       Death of Optionee. If an Optionee dies while a Service Provider, the Option may be exercised
within such period of time as is specified in the Option Agreement (but in no event later than the expiration of the term of such Option as set forth in the Option Agreement), by the Optionee’s designated beneficiary, provided such beneficiary
has been designated prior to Optionee’s death in a form acceptable to the Administrator. If no such beneficiary has been designated by the Optionee, then such Option may be exercised by the personal representative of the Optionee’s estate
or by the person(s) to whom the Option is transferred pursuant to the Optionee’s will or in accordance with the laws of descent and distribution. In the absence of a specified time in the Option Agreement, the vested portion of the Option shall
remain exercisable for twelve (12) months following the Optionee’s termination. If, at the time of death, the Optionee is not vested as to his or her entire Option, the Shares covered by the unvested portion of the Option shall immediately
be forfeited by the Optionee and revert to the Plan. If the Option is not so exercised within the time specified herein, the Option shall terminate, and the Shares covered by such Option shall be forfeited by the Optionee and revert to the Plan.

 (iv)       Separation from Service. In construing the provisions of any Award relating to the
payment of “nonqualified deferred compensation” (subject to Section 409A of the Code) upon a termination or cessation of employment, references to termination or cessation of employment, separation from service, retirement or similar
or correlative terms shall be construed to require a “separation from service” (as that term is defined in Section 1.409A-1(h) of the Treasury Regulations) from the Company and from all other corporations and trades or businesses, if
any, that would be treated as a single “service recipient” with the Company under Section 1.409A-1(h)(3) of the Treasury Regulations. The Company may, but need not, elect in writing, subject to the applicable limitations under
Section 409A, any of the special elective rules prescribed in Section 1.409A-1(h) of the Treasury Regulations for purposes of determining whether a “separation from service” has occurred. Any such written election shall be deemed
a part of the Plan. 
 (c) Leaves of Absence. 

(i)        Unless the Administrator provides otherwise, vesting of Options granted
hereunder shall be suspended during any unpaid leave of absence. 
 (ii)       A Service
Provider shall not cease to be an Employee in the case of (A) any leave of absence approved by the Company or (B) transfers between locations of the Company or between the Company, its Parent, any Subsidiary, or any successor. 

(iii)      For purposes of Incentive Stock Options, no such leave may exceed ninety
(90) days, unless reemployment upon expiration of such leave is guaranteed by statute or contract. If reemployment upon expiration of a leave of absence approved by the Company is not so 

  
 -8- 

 
guaranteed, then three (3) months following the 91st day of such leave, any Incentive Stock Option held by the Optionee shall cease to be
treated as an Incentive Stock Option and shall be treated for tax purposes as a Nonstatutory Stock Option. 
 11.
Transferability of Awards. Unless determined otherwise by the Administrator, Awards may not be sold, pledged, assigned, hypothecated, transferred, or disposed of in any manner other than by will or the laws of descent and distribution, and
may be exercised during the lifetime of the Optionee, only by the Optionee. If the Administrator in its sole discretion makes an Award transferable, such Award may only be transferred (i) by will, (ii) by the laws of descent and
distribution, or (iii) as permitted by Rule 701 of the Securities Act of 1933, as amended. 
 12. Adjustments;
Dissolution or Liquidation; Merger or Change in Control. 
 (a) Adjustments. In the event that any dividend or
other distribution (whether in the form of cash, Shares, other securities, or other property), recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, combination, repurchase, or exchange of
Shares or other securities of the Company, or other change in the corporate structure of the Company affecting the Shares occurs, the Administrator, in order to prevent diminution or enlargement of the benefits or potential benefits intended to be
made available under the Plan, may (in its sole discretion) adjust the number and class of Shares that may be delivered under the Plan and/or the number, class, and price of Shares covered by each outstanding Option. 

(b) Dissolution or Liquidation. In the event of the proposed dissolution or liquidation of the Company, the
Administrator shall notify each Optionee as soon as practicable prior to the effective date of such proposed transaction. To the extent it has not been previously exercised, an Option will terminate immediately prior to the consummation of such
proposed action. 
 (c) Merger or Change in Control. In the event of a merger of the Company with or into another
corporation, or a Change in Control, each outstanding Award shall be assumed or an equivalent award substituted by the successor corporation or a Parent or Subsidiary of the successor corporation. In the event that the successor corporation in a
merger or Change in Control refuses to assume or substitute for the Award, then the Awards shall fully vest, and each Option shall become fully exercisable. If an Option becomes fully vested and exercisable in lieu of assumption or substitution in
the event of a merger or Change in Control, the Administrator shall notify the Optionee in writing or electronically that the Option shall be fully exercisable for a period of time as determined by the Administrator, and the Option shall terminate
upon expiration of such period. For the purposes of this paragraph, an Award shall be considered assumed if, following the merger or Change in Control, the award confers the right to purchase or receive, for each Share subject to the Award
immediately prior to the merger or Change in Control, the consideration (whether stock, cash, or other securities or property) received in the merger or Change in Control by holders of Common Stock for each Share held on the effective date of the
transaction (and if holders were offered a choice of consideration, the type of consideration chosen by the holders of a majority of the outstanding Shares); provided, however, that if such consideration received in the merger or Change in Control
is not solely common stock of the successor corporation or its Parent, the Administrator may, with the consent of the successor corporation, provide for the consideration to be received upon the exercise of the Option or vesting of the Restricted
Stock, for each Share subject to the Option or Restricted Stock, to be solely common stock of the successor corporation or its Parent equal in fair 

  
 -9- 

 
market value to the per share consideration received by holders of common stock in the merger or Change in Control. 

13. Amendment and Termination of the Plan. 

(a) Amendment and Termination.     The Board may at any time amend or alter the Plan or any
outstanding Award for any purposes for which may at the time be permitted by law, and the Board may at any time suspend or terminate the Plan as to any future grants of Options. 

(b) Stockholder Approval.     The Board shall obtain stockholder approval of any Plan amendment to
the extent necessary and desirable to comply with Applicable Laws. 
 (c) Effect of Amendment or Termination.
    Except as otherwise expressly provided in the Plan, the Administrator may not, without the Optionee’s consent, alter the terms of an Award so as to affect materially and adversely the Optionee’s rights under the
Award, unless the Administrator expressly reserved the right to do so at the time the Award was granted. Termination of the Plan shall not affect the Administrator’s ability to exercise the powers granted to it hereunder with respect to Awards
granted under the Plan prior to the date of such termination. 
 14. Conditions Upon Issuance of Shares. 

(a) Legal Compliance.     Shares shall not be issued pursuant to the exercise of an Option unless
the exercise of such Option and the issuance and delivery of such Shares shall comply with Applicable Laws and shall be further subject to the approval of counsel for the Company with respect to such compliance. 

(b) Certificates.     The Company may require that a certificate evidencing Shares issued under
the Plan bear an appropriate legend reflecting any restrictions on transfer applicable to such Shares and the Company may hold the certificates pending lapse of the applicable restrictions. 

(c) Investment Representations.     As a condition to the exercise of an Option, the Administrator
may require the person exercising such Option to represent and warrant at the time of any such exercise that the Shares are being purchased only for investment and without any present intention to sell or distribute such Shares if, in the opinion of
counsel for the Company, such a representation is required. 
 15. Inability to Obtain Authority.
    The inability of the Company to obtain authority from any regulatory body having jurisdiction, which authority is deemed by the Company’s counsel to be necessary to the lawful issuance and sale of any Shares hereunder,
shall relieve the Company of any liability in respect of the failure to issue or sell such Shares as to which such requisite authority shall not have been obtained. 

16. Reservation of Shares.     The Company, during the term of this Plan, shall at all times
reserve and keep available such number of Shares as shall be sufficient to satisfy the requirements of the Plan. 

  
 -10- 

 17. Stockholder Approval. The Plan shall be subject to approval by the
stockholders of the Company within twelve (12) months after the date the Plan is adopted. Such stockholder approval shall be obtained in the degree and manner required under Applicable Laws. 

18. Miscellaneous 

(a) Award Provisions. By accepting (or, under such rules as the Administrator may prescribe, being deemed to have
accepted) an Award, the Optionee shall be deemed to have agreed to the terms of the Award and the Plan. 
 (b)
Coordination with Other Plans. Awards under the Plan may be granted in tandem with, or in satisfaction of or substitution for, other Awards under the Plan or awards made under other compensatory plans or programs of the Company or its
subsidiaries. For example, but without limiting the generality of the foregoing, awards under other compensatory plans or programs of the Company or its subsidiaries may be settled in Shares if the Administrator so determines, in which case the
shares delivered will be treated as awarded under the Plan (and will reduce the number of shares thereafter available under the Plan in accordance with the rules set forth in Section 3). 

(c) Taxes. The delivery, vesting and retention of Shares under an Award are conditioned upon full satisfaction by the
Optionee of all tax withholding requirements with respect to the Award. The Administrator will prescribe such rules for the withholding of taxes as it deems necessary. The Administrator may, but need not, hold back Shares from an Award or permit an
Optionee to tender previously owned Shares in satisfaction of tax withholding requirements (but not in excess of the minimum withholding required by law). 

(d) Section 409A. Each Award may contain such terms as the Administrator determines, and shall be construed and administered,
such that the Award either (i) qualifies for an exemption from the requirements of Section 409A, or (ii) satisfies such requirements. 

(e) Certain Requirements of Corporate Law. Awards shall be granted and administered consistent with the requirements of Applicable Law
relating to the issuance of stock and the consideration to be received therefor, and with the applicable requirements of the stock exchanges or other trading systems on which the Common Stock is listed or entered for trading, in each case as
determined by the Administrator. 
 (f) Waiver of Jury Trial. By accepting an Award under the Plan, each Optionee waives any right
to a trial by jury in any action, proceeding or counterclaim concerning any rights under the Plan and any Award, or under any amendment, waiver, consent, instrument, document or other agreement delivered or which in the future may be delivered in
connection therewith, and agrees that any such action, proceedings or counterclaim shall be tried before a court and not before a jury. By accepting an Award under the Plan, each Optionee certifies that no officer, representative, or attorney of the
Company has represented, expressly or otherwise, that the Company would not, in the event of any action, proceeding or counterclaim, seek to enforce the foregoing waivers. 

(g) Limitation of Liability. Notwithstanding anything to the contrary in the Plan, neither the Company, nor any affiliate, nor the
Administrator, nor any person acting on behalf of the Company, any affiliate, or the Administrator, will be liable to any Optionee or to the estate or beneficiary of any Optionee or to any other holder of an Award by reason of any acceleration of

  
 -11- 

 
income, or any additional tax (including any interest and penalties), asserted by reason of the failure of an Award to satisfy the requirements of Section 422 or Section 409A of the
Code or by reason of Section 4999 of the Code, or otherwise asserted with respect to the Award; provided, that nothing in this Section 18(g) will limit the ability of the Administrator or the Company, in its discretion, to provide by
separate express written agreement with an Optionee for a gross-up payment or other payment in connection with any such acceleration of income or additional tax. 

(h) Establishment of Sub-Plans. The Board may from time to time establish one or more sub-plans under the Plan for purposes of
satisfying applicable blue sky, securities or tax laws of various jurisdictions. The Board will establish such sub-plans by adopting supplements to the Plan setting forth (i) such limitations on the Administrator’s discretion under the
Plan as the Board deems necessary or desirable and (ii) such additional terms and conditions not otherwise inconsistent with the Plan as the Board deems necessary or desirable. All supplements adopted by the Board will be deemed to be part of
the Plan, but each supplement will apply only to Optionees within the affected jurisdiction and the Company will not be required to provide copies of any supplement to Optionees in any jurisdiction that is not affected. 

(i) Additional Requirement to Provide Information to California Participants. The Company shall provide to each holder of an Award not
less frequently than annually during the period such individual has one or more Awards outstanding, and, in the case of an individual who acquires Shares pursuant to the Plan, during the period such individual owns such Shares, copies of annual
financial statements. The Company shall not be required to provide such statements to key Employees whose duties in connection with the Company assure their access to equivalent information. 

19. Governing Law. 
 (a)
Certain Requirements of Corporate Law. Awards will be granted and administered consistent with the requirements of applicable Delaware law relating to the issuance of stock and the consideration to be received therefor, and with the
applicable requirements of the stock exchanges or other trading systems on which the Shares are listed or entered for trading, in each case as determined by the Board. 

(b) Other Matters. Except as otherwise provided by the express terms of an Award, under a sub-plan described in Section 18(h) or
as provided in Section 19(a) above, the provisions of the Plan and of Awards under the Plan and all claims or disputes arising out of our based upon the Plan or any Award under the Plan or relating to the subject matter hereof or thereof will
be governed by and construed in accordance with the domestic substantive laws of the State of California without giving effect to any choice or conflict of laws provision or rule that would cause the application of the domestic substantive laws of
any other jurisdiction. 

  
 -12- 

 CARBYLAN THERAPEUTICS, INC. 

2014 STOCK OPTION PLAN 

STOCK OPTION AGREEMENT 

Unless otherwise defined herein, the terms defined in the 2014 Stock Option Plan shall have the same defined meanings in this
Stock Option Agreement. 
  

	I.	 NOTICE OF GRANT 

Optionee: 

The undersigned Optionee has been granted an Option to purchase Common Stock of the Company, subject to the terms and
conditions of the Plan and this Option Agreement, as follows: 
  

					
	 Date of Grant
	  	  
	  	
			
	 Vesting Commencement Date
	  	  
	  	
			
	 Exercise Price per Share
	  	     $
	  	
			
	 Total Number of Shares Granted
	  	  
	  	
			
	 Total Exercise Price
	  	     $
	  	
			
	 Type of Option:
	  	
                            
  Incentive Stock Option
	  	
			
		  	
                            
  Nonstatutory Stock Option
	  	
			
	 Expiration Date:
	  	  
	  	

 Vesting Schedule: 

This Option shall be exercisable in whole or in part according to the following vesting schedule: 

 Termination Period: 

This Option shall be exercisable for three months after the Optionee ceases to be a Service Provider. Upon the Optionee’s
death or Disability, this Option shall be exercisable for one year after Optionee ceases to be Service Provider. In no event may the Optionee exercise this Option after the Expiration Date set forth above. 

 

	II.	 AGREEMENT 

1.      Grant of Option. The Company hereby grants to the Optionee named in the Notice of
Grant in Part I of this Agreement (the “Optionee”), an option (the “Option”) to purchase the number of Shares set forth in the Notice of Grant, at the Exercise Price per Share set forth in the Notice
of Grant (the “Exercise Price”), and subject to the terms and conditions of the Plan, which is incorporated herein by reference. In the event of a conflict between the terms and conditions of the Plan and this Option
Agreement, the terms and conditions of the Plan shall prevail. 
 If designated in the Notice of Grant as an Incentive
Stock Option (“ISO”), this Option is intended to qualify as an Incentive Stock Option as defined in Section 422 of the Code. Nevertheless, to the extent that it exceeds the $100,000 rule of Code Section 422(d), this
Option shall be treated as a Nonstatutory Stock Option (“NSO”). 

2.      Exercise of Option. This Option shall be exercisable during its term in
accordance with the provisions of Section 10 of the Plan as follows: 

(a)      Right to Exercise. 

(i)       Subject to subsections 2(a)(ii) and 2(b) below, this Option shall be
exercisable according to the vesting schedule set forth in the Notice of Grant. 

(ii)      This Option may not be exercised for a fraction of a Share. 

(b)      Method of Exercise. This Option shall be exercisable by delivery of an exercise
notice in the form attached as Exhibit A (the “Exercise Notice”). The Exercise Notice shall be accompanied by payment of the aggregate Exercise Price as to the portion of this Option so exercised. This Option
shall be deemed to be exercised upon receipt by the Company of such fully executed Exercise Notice accompanied by full payment of the aggregate Exercise Price by one of the methods set forth in Section 5 below and satisfaction of all tax
withholding requirements by such methods as permitted under the Plan. 

3.      Optionee’s Representations. In the event the Shares have not been registered
under the Securities Act of 1933, as amended (the “Securities Act”), at the time this Option is exercised, the Optionee shall, if required by the Company, concurrently with the exercise of all or any portion of this Option,
deliver to the Company an Investment Representation Statement in the form attached hereto as Exhibit B. 

4.      Lock-Up Period. The Optionee hereby agrees that the Optionee shall not offer,
pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of,

  
 -2- 

 
directly or indirectly, any Common Stock (or other securities) of the Company or enter into any swap, hedging or other arrangement that transfers to another, in whole or in part, any of the
economic consequences of ownership of any Common Stock (or other securities) of the Company held by the Optionee (other than those included in the registration) for a period specified by the representative of the underwriters of Common Stock (or
other securities) of the Company not to exceed one hundred eighty (180) days following the effective date of any registration statement of the Company filed under the Securities Act. 

The Optionee agrees to execute and deliver such other agreements as may be reasonably requested by the Company or the
underwriter which are consistent with the foregoing or which are necessary to give further effect thereto. In addition, if requested by the Company or the representative of the underwriters of Common Stock (or other securities) of the Company, the
Optionee shall provide, within ten (10) days of such request, such information as may be required by the Company or such representative in connection with the completion of any public offering of the Company’s securities pursuant to a
registration statement filed under the Securities Act. The obligations described in this Section shall not apply to a registration relating solely to employee benefit plans on Form S-1 or Form S-8 or similar forms that may be promulgated in the
future, or a registration relating solely to a Commission Rule 145 transaction on Form S-4 or similar forms that may be promulgated in the future. The Company may impose stop-transfer instructions with respect to the shares of Common Stock (or other
securities) subject to the foregoing restriction until the end of said one hundred eighty (180) day period. The Optionee agrees that any transferee of the Option or shares acquired pursuant to the Option shall be bound by this Section. 

5.      Method of Payment. Payment of the aggregate Exercise Price shall be by any of the
following, or a combination thereof, at the election of the Optionee: 
 (a)      cash; 

(b)      check; 

(c)      consideration received by the Company under a formal cashless exercise program adopted
by the Company in connection with the Plan; or 
 (d)      surrender of other Shares which,
(i) in the case of Shares acquired from the Company, either directly or indirectly, have been owned by the Optionee for more than six (6) months on the date of surrender, and (ii) have a Fair Market Value on the date of surrender
equal to the aggregate Exercise Price of the portion of this Option exercised.. 
 6.      
Non-Transferability of Option. This Option may not be transferred in any manner otherwise than by will or by the laws of descent or distribution or as set forth in the Plan and may be exercised during the lifetime of the Optionee only by the
Optionee. The terms of the Plan and this Option Agreement shall be binding upon the executors, administrators, heirs, successors and assigns of the Optionee. 

7.       Notice of Disqualifying Disposition of ISO Shares. If the Option granted to the
Optionee herein is an ISO, and if the Optionee sells or otherwise disposes of any of the Shares acquired pursuant to the ISO on or before the later of (1) the date two years after the Date of Grant, and (2) the date one year after the date
of exercise, the Optionee shall immediately notify the 

  
 -3- 

 
Company in writing of such disposition. The Optionee agrees that the Optionee may be subject to income tax withholding by the Company on the compensation income recognized by the Optionee. 

8.      Entire Agreement. The Plan is incorporated herein by reference. The Plan and this
Option Agreement constitute the entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of the Company and the Optionee with respect to the subject matter
hereof, and may not be modified adversely to the Optionee’s interest except by means of a writing signed by the Company and the Optionee. 

9.      No Guarantee of Continued Service. THE OPTIONEE AGREES THAT THE VESTING OF SHARES
PURSUANT TO THE VESTING SCHEDULE HEREOF IS EARNED ONLY BY CONTINUING AS A SERVICE PROVIDER AT THE WILL OF THE COMPANY (NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED THIS OPTION OR ACQUIRING SHARES HEREUNDER). THE OPTIONEE FURTHER ACKNOWLEDGES
AND AGREES THAT THIS AGREEMENT, THE TRANSACTIONS CONTEMPLATED HEREUNDER AND THE VESTING SCHEDULE SET FORTH HEREIN DO NOT CONSTITUTE AN EXPRESS OR IMPLIED PROMISE OF CONTINUED ENGAGEMENT AS A SERVICE PROVIDER FOR THE VESTING PERIOD, FOR ANY PERIOD,
OR AT ALL, AND SHALL NOT INTERFERE IN ANY WAY WITH THE OPTIONEE’S RIGHT OR THE COMPANY’S RIGHT TO TERMINATE THE OPTIONEE’S RELATIONSHIP AS A SERVICE PROVIDER AT ANY TIME, WITH OR WITHOUT CAUSE. 

The Optionee acknowledges receipt of a copy of the Plan and represents that he or she is familiar with the terms and
provisions thereof, and hereby accepts this Option subject to all of the terms and provisions thereof. The Optionee has reviewed the Plan and this Option in their entirety, has had an opportunity to obtain the advice of counsel prior to executing
this Option and fully understands all provisions of the Option. The Optionee hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan or this Option. The
Optionee further agrees to notify the Company upon any change in the residence address indicated below. 
  

									
	 OPTIONEE
	 		 		 	 CARBYLAN THERAPEUTICS, INC.

				
	  
	 		 	 By:
	 	  

	 Signature
	 		 		 	
					
	 Address:
	 	  
	 		 	 Title:
	 	  

					
		 	  
	 		 		 	

  
 -4- 

 EXHIBIT A 

2014 STOCK OPTION PLAN 

EXERCISE NOTICE 
 Carbylan Therapeutics,
Inc. 
 Attention: President 

1.      Exercise of Option. Effective as of today,
                        ,             , the undersigned
(“Optionee”) hereby elects to exercise Optionee’s option (the “Option”) to purchase
                         shares of the Common Stock (the “Shares”) of Carbylan Therapeutics,
Inc. (the “Company”) under and pursuant to the 2014 Stock Option Plan (the “Plan”) and the Stock Option Agreement dated
                        ,              (the
“Option Agreement”). Except as otherwise defined herein, all capitalized terms have the same meaning as in the Plan. 

2.      Delivery of Payment. Optionee herewith delivers to the Company the full purchase
price of the Shares, as set forth in the Option Agreement, and any and all withholding taxes due in connection with the exercise of the Option. 

3.      Representations of Optionee. Optionee acknowledges that Optionee has received,
read and understood the Plan and the Option Agreement and agrees to abide by and be bound by their terms and conditions. 

4.      Rights as Stockholder. Until the issuance of the Shares (as evidenced by the
appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company), no right to vote or receive dividends or any other rights as a stockholder shall exist with respect to the Optioned Stock, notwithstanding the
exercise of the Option. The Shares shall be issued to the Optionee as soon as practicable after the Option is exercised in accordance with the Option Agreement. 

5.      Company’s Right of First Refusal. Before any Shares held by Optionee or any
transferee (either being sometimes referred to herein as the “Holder”) may be sold or otherwise transferred (including transfer by gift or operation of law), the Company or its assignee(s) shall have a right of first refusal
to purchase the Shares on the terms and conditions set forth in this Section (the “Right of First Refusal”). 

(a)      Notice of Proposed Transfer. The Holder of the Shares shall deliver to the
Company a written notice (the “Notice”) stating: (i) the Holder’s bona fide intention to sell or otherwise transfer such Shares; (ii) the name of each proposed purchaser or other transferee
(“Proposed Transferee”); (iii) the number of Shares to be transferred to each Proposed Transferee; and (iv) the bona fide cash price or other consideration for which the Holder proposes to transfer the Shares (the
“Offered Price”), and the Holder shall offer the Shares at the Offered Price to the Company or its assignee(s). 

 (b)      Exercise of Right of First
Refusal. At any time within thirty (30) days after receipt of the Notice, the Company and/or its assignee(s) may, by giving written notice to the Holder, elect to purchase all, but not less than all, of the Shares proposed to be transferred
to any one or more of the Proposed Transferees, at the purchase price determined in accordance with subsection (c) below. 

(c)      Purchase Price. The purchase price (“Purchase Price”)
for the Shares purchased by the Company or its assignee(s) under this Section shall be the Offered Price. If the Offered Price includes consideration other than cash, the cash equivalent value of the non-cash consideration shall be determined by the
Board of Directors of the Company in good faith. 
 (d)      Payment. Payment of the
Purchase Price shall be made, at the option of the Company or its assignee(s), in cash (by check), by cancellation of all or a portion of any outstanding indebtedness of the Holder to the Company (or, in the case of repurchase by an assignee, to the
assignee), or by any combination thereof within 30 days after receipt of the Notice or in the manner and at the times set forth in the Notice. 

(e)      Holder’s Right to Transfer. If all of the Shares proposed in the Notice to
be transferred to a given Proposed Transferee are not purchased by the Company and/or its assignee(s) as provided in this Section, then the Holder may sell or otherwise transfer such Shares to that Proposed Transferee at the Offered Price or at a
higher price, provided that such sale or other transfer is consummated within 120 days after the date of the Notice, that any such sale or other transfer is effected in accordance with any applicable securities laws and that the Proposed Transferee
agrees in writing that the provisions of this Section shall continue to apply to the Shares in the hands of such Proposed Transferee. If the Shares described in the Notice are not transferred to the Proposed Transferee within such period, a new
Notice shall be given to the Company, and the Company and/or its assignees shall again be offered the Right of First Refusal before any Shares held by the Holder may be sold or otherwise transferred. 

(f)      Exception for Certain Family Transfers. Anything to the contrary contained in
this Section notwithstanding, the transfer of any or all of the Shares during Optionee’s lifetime or on Optionee’s death by will or intestacy to Optionee’s immediate family or a trust for the benefit of Optionee’s immediate
family shall be exempt from the provisions of this Section. “Immediate Family” as used herein shall mean spouse, lineal descendant or antecedent, father, mother, brother or sister. In such case, the transferee or other
recipient shall receive and hold the Shares so transferred subject to the provisions of this Section, and there shall be no further transfer of such Shares except in accordance with the terms of this Section. 

(g)      Termination of Right of First Refusal. The Right of First Refusal shall
terminate as to any Shares upon the earlier of (i) first sale of Common Stock of the Company to the general public, or (ii) a Change in Control in which the successor corporation has equity securities that are publicly traded. 

6.      Tax Consultation. Optionee understands that Optionee may suffer adverse tax
consequences as a result of Optionee’s purchase or disposition of the Shares. Optionee represents that Optionee has consulted with any tax consultants Optionee deems advisable in connection with

  
 -2- 

 
the purchase or disposition of the Shares and that Optionee is not relying on the Company for any tax advice. 

7.      Restrictive Legends and Stop-Transfer Orders. 

(a)      Legends. Optionee understands and agrees that the Company shall cause the
legends set forth below or legends substantially equivalent thereto, to be placed upon any certificate(s) evidencing ownership of the Shares together with any other legends that may be required by the Company or by state or federal securities laws:

 THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. THEY MAY NOT BE SOLD, OFFERED FOR SALE,
PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THE SECURITIES UNDER SAID ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED. THIS CERTIFICATE MUST BE SURRENDERED TO
THE COMPANY OR ITS TRANSFER AGENT AS A CONDITION PRECEDENT TO THE SALE, PLEDGE OR OTHER TRANSFER OF ANY INTEREST IN ANY OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE. 

THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO RESTRICTIONS ON TRANSFER AS SET FORTH IN AN AGREEMENT BETWEEN THE
COMPANY AND THE REGISTERED HOLDER, OR HIS PREDECESSOR IN INTEREST, A COPY OF WHICH IS ON FILE AT THE PRINCIPAL OFFICE OF THE COMPANY. 

(b)      Stop-Transfer Notices. Optionee agrees that, in order to ensure compliance with
the restrictions referred to herein, the Company may issue appropriate “stop transfer” instructions to its transfer agent, if any, and that, if the Company transfers its own securities, it may make appropriate notations to the same
effect in its own records. 
 (c)      Refusal to Transfer. The Company shall not be
required (i) to transfer on its books any Shares that have been sold or otherwise transferred in violation of any of the provisions of this Exercise Notice or (ii) to treat as owner of such Shares or to accord the right to vote or pay
dividends to any purchaser or other transferee to whom such Shares shall have been so transferred. 

8.      Successors and Assigns. The Company may assign any of its rights under this
Exercise Notice to single or multiple assignees, and this Exercise Notice shall inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer herein set forth, this Exercise Notice shall be binding upon
Optionee and his or her heirs, executors, administrators, successors and assigns. 

9.      Interpretation. Any dispute regarding the interpretation of this Exercise Notice
shall be submitted by Optionee or by the Company forthwith to the Administrator, which shall review such dispute at its next regular meeting. The resolution of such a dispute by the Administrator shall be final and binding on all parties. 

  
 -3- 

 10.      Governing Law. This Exercise Notice
will be administered consistent with the requirements of applicable Delaware law relating to the issuance of stock and the consideration to be received therefor, and with the applicable requirements of the stock exchanges or other trading systems on
which the Shares are listed or entered for trading, in each case as determined by the Board. Except as otherwise provided in the preceding sentence, the provisions of this Exercise Notice and all claims or disputes arising out of our based upon this
Exercise Notice or relating to the subject matter hereof will be governed by and construed in accordance with the domestic substantive laws of the State of California without giving effect to any choice or conflict of laws provision or rule that
would cause the application of the domestic substantive laws of any other jurisdiction. 

11.      Entire Agreement. The Plan and Option Agreement are incorporated herein by
reference. This Exercise Notice, the Plan, the Option Agreement and the Investment Representation Statement constitute the entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior
undertakings and agreements of the Company and Optionee with respect to the subject matter hereof, and may not be modified adversely to Optionee’s interest except by means of a writing signed by the Company and Optionee. 

 

					
	 Submitted by:
	  		  	 Accepted by:

			
	 OPTIONEE
	  		  	 CARBYLAN THERAPEUTICS, INC.

			
	  
	  		  	  

	 Signature
	  		  	 By

	  
	  		  	
	 Print Name
	  		  	 Its

			
	 Address:
	  		  	 Address:

			
	  
	  		  	  

	  
	  		  	  

	  
	  		  	  

			
		  		  	  

		  		  	 Date Received

  
 -4- 

 EXHIBIT B 

INVESTMENT REPRESENTATION STATEMENT 
  

					
	 OPTIONEE
	  	:	  	
			
	 COMPANY
	  	:	  	 CARBYLAN THERAPEUTICS, INC.

			
	 SECURITY
	  	:	  	 COMMON STOCK

			
	 AMOUNT
	  	:	  	
			
	 DATE
	  	:	  	

 In connection with the purchase of the above-listed securities (“Securities”), the
undersigned Optionee represents to the Company the following: 
 (a)      Optionee is aware
of the Company’s business affairs and financial condition and has acquired sufficient information about the Company to reach an informed and knowledgeable decision to acquire the Securities. Optionee is acquiring these Securities for investment
for Optionee’s own account only and not with a view to, or for resale in connection with, any “distribution” thereof within the meaning of the Securities Act of 1933, as amended (the “Securities Act”). 

(b)      Optionee acknowledges and understands that the Securities constitute “restricted
securities” under the Securities Act and have not been registered under the Securities Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of Optionee’s investment
intent as expressed herein. In this connection, Optionee understands that, in the view of the Securities and Exchange Commission, the statutory basis for such exemption may be unavailable if Optionee’s representation was predicated solely upon
a present intention to hold these Securities for the minimum capital gains period specified under tax statutes, for a deferred sale, for or until an increase or decrease in the market price of the Securities, or for a period of one year or any other
fixed period in the future. Optionee further understands that the Securities must be held indefinitely unless they are subsequently registered under the Securities Act or an exemption from such registration is available. Optionee further
acknowledges and understands that the Company is under no obligation to register the Securities. Optionee understands that the certificate evidencing the Securities will be imprinted with any legend required under applicable state securities laws.

 (c)      Optionee is familiar with the provisions of Rule 701 and Rule 144, each
promulgated under the Securities Act, which, in substance, permit limited public resale of “restricted securities” acquired, directly or indirectly from the issuer thereof, in a non-public offering subject to the satisfaction of certain
conditions. Rule 701 provides that if the issuer qualifies under Rule 701 at the time of the grant of the Option to Optionee, the exercise will be exempt from registration under the Securities Act. In the event the Company becomes subject
to the reporting requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, ninety (90) days thereafter (or such 

 
longer period as any market stand-off agreement may require) the Securities exempt under Rule 701 may be resold, subject to the satisfaction of certain of the conditions specified by
Rule 144, including: (1) the resale being made through a broker in an unsolicited “broker’s transaction” or in transactions directly with a market maker (as said term is defined under the Securities Exchange Act of
1934); and, in the case of an affiliate, (2) the availability of certain public information about the Company, (3) the amount of Securities being sold during any three month period not exceeding the limitations specified in
Rule 144(e), and (4) the timely filing of a Form 144, if applicable. 
   In the event that the Company
does not qualify under Rule 701 at the time of grant of the Option, then the Securities may be resold in certain limited circumstances subject to the provisions of Rule 144. 

(d)      Optionee further understands that in the event all of the applicable requirements of
Rule 701 or 144 are not satisfied, registration under the Securities Act, compliance with Regulation A, or some other registration exemption will be required; and that, notwithstanding the fact that Rules 144 and 701 are not exclusive, the
Staff of the Securities and Exchange Commission has expressed its opinion that persons proposing to sell private placement securities other than in a registered offering and otherwise than pursuant to Rules 144 or 701 will have a substantial burden
of proof in establishing that an exemption from registration is available for such offers or sales, and that such persons and their respective brokers who participate in such transactions do so at their own risk. Optionee understands that no
assurances can be given that any such other registration exemption will be available in such event. 
  

			
	 Signature of Optionee:

	
	  

		
	 Date:
	 	  

  
 -2- 

 CARBYLAN THERAPEUTICS, INC. 

2014 STOCK OPTION PLAN 

STOCK OPTION AGREEMENT— EARLY EXERCISE 

Unless otherwise defined herein, the terms defined in the 2014 Stock Option Plan shall have the same defined meanings in this
Stock Option Agreement. 
  

	I.	 NOTICE OF GRANT 

Optionee: 

The undersigned Optionee has been granted an Option to purchase Common Stock of the Company, subject to the terms and
conditions of the Plan and this Option Agreement, as follows: 
  

					
	 Date of Grant
	  	  
	  	
			
	 Vesting Commencement Date
	  	  
	  	
			
	 Exercise Price per Share
	  	     $
	  	
			
	 Total Number of Shares Granted
	  	  
	  	
			
	 Total Exercise Price
	  	     $
	  	
			
	 Type of Option:
	  	
                            
  Incentive Stock Option
	  	
			
		  	
                            
  Nonstatutory Stock Option
	  	
			
	 Expiration Date:
	  	  
	  	

 Vesting Schedule: 

This Option shall be exercisable in whole or in part according to the following vesting schedule: 

 Termination Period: 

This Option shall be exercisable for three months after the Optionee ceases to be a Service Provider. Upon the Optionee’s
death or Disability, this Option shall be exercisable for one year after Optionee ceases to be Service Provider. In no event may the Optionee exercise this Option after the Expiration Date set forth above. 

 

	II.	 AGREEMENT 

1.       Grant of Option. The Company hereby grants to the Optionee named in the Notice
of Grant in Part I of this Agreement (the “Optionee”), an option (the “Option”) to purchase the number of Shares set forth in the Notice of Grant, at the Exercise Price per Share set forth in the
Notice of Grant (the “Exercise Price”), and subject to the terms and conditions of the Plan, which is incorporated herein by reference. In the event of a conflict between the terms and conditions of the Plan and this Option
Agreement, the terms and conditions of the Plan shall prevail. 
 If designated in the Notice of Grant as an Incentive
Stock Option (“ISO”), this Option is intended to qualify as an Incentive Stock Option as defined in Section 422 of the Code. Nevertheless, to the extent that it exceeds the $100,000 rule of Code Section 422(d), this
Option shall be treated as a Nonstatutory Stock Option (“NSO”). 

2.       Exercise of Option. This Option shall be exercisable during its term in
accordance with the provisions of Section 10 of the Plan as follows: 
 (a)      
Right to Exercise. 
 (i)        Subject to subsections 2(a)(ii),
2(a)(iii) and 2(b) below, this Option shall be exercisable according to the vesting schedule set forth in the Notice of Grant. Alternatively, at the election of the Optionee, this Option may be exercised in whole or in part at any time as to Shares
that have not yet vested. Vested Shares shall not be subject to the Company’s repurchase right (as set forth in the Restricted Stock Purchase Agreement, attached hereto as Exhibit C-1). 

(ii)       As a condition to exercising this Option for unvested Shares, the Optionee
shall execute the Restricted Stock Purchase Agreement. 
 (iii)      This Option may not be
exercised for a fraction of a Share. 
 (b)       Method of Exercise. This Option
shall be exercisable by delivery of an exercise notice in the form attached as Exhibit A (the “Exercise Notice”). The Exercise Notice shall be accompanied by payment of the aggregate Exercise Price as to the
portion of this Option so exercised. This Option shall be deemed to be exercised upon receipt by the Company of such fully executed Exercise Notice accompanied by full payment of the aggregate Exercise Price by one of the methods set forth in
Section 5 below and satisfaction of all tax withholding requirements by such methods as permitted under the Plan. 

  
 -2- 

 3.       Optionee’s Representations. In
the event the Shares have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), at the time this Option is exercised, the Optionee shall, if required by the Company, concurrently with the
exercise of all or any portion of this Option, deliver to the Company an Investment Representation Statement in the form attached hereto as Exhibit B. 

4.       Lock-Up Period. The Optionee hereby agrees that the Optionee shall not offer,
pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any Common Stock (or
other securities) of the Company or enter into any swap, hedging or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any Common Stock (or other securities) of the Company held by the
Optionee (other than those included in the registration) for a period specified by the representative of the underwriters of Common Stock (or other securities) of the Company not to exceed one hundred eighty (180) days following the effective
date of any registration statement of the Company filed under the Securities Act. 
 The Optionee agrees to execute and
deliver such other agreements as may be reasonably requested by the Company or the underwriter which are consistent with the foregoing or which are necessary to give further effect thereto. In addition, if requested by the Company or the
representative of the underwriters of Common Stock (or other securities) of the Company, the Optionee shall provide, within ten (10) days of such request, such information as may be required by the Company or such representative in connection
with the completion of any public offering of the Company’s securities pursuant to a registration statement filed under the Securities Act. The obligations described in this Section shall not apply to a registration relating solely to employee
benefit plans on Form S-1 or Form S-8 or similar forms that may be promulgated in the future, or a registration relating solely to a Commission Rule 145 transaction on Form S-4 or similar forms that may be promulgated in the future. The Company may
impose stop-transfer instructions with respect to the shares of Common Stock (or other securities) subject to the foregoing restriction until the end of said one hundred eighty (180) day period. The Optionee agrees that any transferee of the
Option or shares acquired pursuant to the Option shall be bound by this Section. 
 5.      
Method of Payment. Payment of the aggregate Exercise Price shall be by any of the following, or a combination thereof, at the election of the Optionee: 

(a)       cash; 

(b)       check; 

(c)       consideration received by the Company under a formal cashless exercise program
adopted by the Company in connection with the Plan; or 
 (d)       surrender of other Shares
which, (i) in the case of Shares acquired from the Company, either directly or indirectly, have been owned by the Optionee for more than six (6) months on the date of surrender, and (ii) have a Fair Market Value on the date of
surrender equal to the aggregate Exercise Price of the portion of this Option exercised. 

  
 -3- 

 6.       Non-Transferability of Option. This
Option may not be transferred in any manner otherwise than by will or by the laws of descent or distribution or as set forth in the Plan and may be exercised during the lifetime of the Optionee only by the Optionee. The terms of the Plan and this
Option Agreement shall be binding upon the executors, administrators, heirs, successors and assigns of the Optionee. 

7.       Notice of Disqualifying Disposition of ISO Shares. If the Option granted to the
Optionee herein is an ISO, and if the Optionee sells or otherwise disposes of any of the Shares acquired pursuant to the ISO on or before the later of (1) the date two years after the Date of Grant, and (2) the date one year after the date
of exercise, the Optionee shall immediately notify the Company in writing of such disposition. The Optionee agrees that the Optionee may be subject to income tax withholding by the Company on the compensation income recognized by the Optionee. 

8.       Entire Agreement. The Plan is incorporated herein by reference. The Plan and
this Option Agreement constitute the entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of the Company and the Optionee with respect to the subject matter
hereof, and may not be modified adversely to the Optionee’s interest except by means of a writing signed by the Company and the Optionee. 

9.       No Guarantee of Continued Service. THE OPTIONEE AGREES THAT THE VESTING OF
SHARES PURSUANT TO THE VESTING SCHEDULE HEREOF IS EARNED ONLY BY CONTINUING AS A SERVICE PROVIDER AT THE WILL OF THE COMPANY (NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED THIS OPTION OR ACQUIRING SHARES HEREUNDER). THE OPTIONEE FURTHER
ACKNOWLEDGES AND AGREES THAT THIS AGREEMENT, THE TRANSACTIONS CONTEMPLATED HEREUNDER AND THE VESTING SCHEDULE SET FORTH HEREIN DO NOT CONSTITUTE AN EXPRESS OR IMPLIED PROMISE OF CONTINUED ENGAGEMENT AS A SERVICE PROVIDER FOR THE VESTING PERIOD, FOR
ANY PERIOD, OR AT ALL, AND SHALL NOT INTERFERE IN ANY WAY WITH THE OPTIONEE’S RIGHT OR THE COMPANY’S RIGHT TO TERMINATE THE OPTIONEE’S RELATIONSHIP AS A SERVICE PROVIDER AT ANY TIME, WITH OR WITHOUT CAUSE. 

The Optionee acknowledges receipt of a copy of the Plan and represents that he or she is familiar with the terms and
provisions thereof, and hereby accepts this Option subject to all of the terms and provisions thereof. The Optionee has reviewed the Plan and this Option in their entirety, has had an opportunity to obtain the advice of counsel prior to executing
this Option and fully understands all provisions of the Option. The Optionee hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan or this Option. The
Optionee further agrees to notify the Company upon any change in the residence address indicated below. 
  

									
	 OPTIONEE
	 		  		  	 CARBYLAN THERAPEUTICS, INC.

				
	  
	  		  	By:	 	 
	 Signature
	  		  		 	
					
	 Address:
	 	  
	  		  	 Title:
	 	  

		 	  
	  		  		 	

  
 -4- 

 EXHIBIT A 

2014 STOCK OPTION PLAN 

EXERCISE NOTICE 
 Carbylan Therapeutics,
Inc. 
 Attention: President 

1.       Exercise of Option. Effective as of today,
                        ,             , the undersigned
(“Optionee”) hereby elects to exercise Optionee’s option (the “Option”) to purchase
                        shares of the Common Stock (the “Shares”) of Carbylan Therapeutics, Inc.
(the “Company”) under and pursuant to the 2014 Stock Option Plan (the “Plan”) and the Stock Option Agreement dated
                        ,             (the
“Option Agreement”). Except as otherwise defined herein, all capitalized terms have the same meaning as in the Plan. 

2.       Delivery of Payment. Optionee herewith delivers to the Company the full purchase
price of the Shares, as set forth in the Option Agreement, and any and all withholding taxes due in connection with the exercise of the Option. 

3.       Representations of Optionee. Optionee acknowledges that Optionee has received,
read and understood the Plan and the Option Agreement and agrees to abide by and be bound by their terms and conditions. 

4.       Rights as Stockholder. Until the issuance of the Shares (as evidenced by the
appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company), no right to vote or receive dividends or any other rights as a stockholder shall exist with respect to the Optioned Stock, notwithstanding the
exercise of the Option. The Shares shall be issued to the Optionee as soon as practicable after the Option is exercised in accordance with the Option Agreement. 

5.       Company’s Right of First Refusal. Before any Shares held by Optionee or any
transferee (either being sometimes referred to herein as the “Holder”) may be sold or otherwise transferred (including transfer by gift or operation of law), the Company or its assignee(s) shall have a right of first refusal
to purchase the Shares on the terms and conditions set forth in this Section (the “Right of First Refusal”). 

(a)       Notice of Proposed Transfer. The Holder of the Shares shall deliver to the
Company a written notice (the “Notice”) stating: (i) the Holder’s bona fide intention to sell or otherwise transfer such Shares; (ii) the name of each proposed purchaser or other transferee
(“Proposed Transferee”); (iii) the number of Shares to be transferred to each Proposed Transferee; and (iv) the bona fide cash price or other consideration for which the Holder proposes to transfer the Shares (the
“Offered Price”), and the Holder shall offer the Shares at the Offered Price to the Company or its assignee(s). 

 (b)       Exercise of Right of First
Refusal. At any time within thirty (30) days after receipt of the Notice, the Company and/or its assignee(s) may, by giving written notice to the Holder, elect to purchase all, but not less than all, of the Shares proposed to be transferred
to any one or more of the Proposed Transferees, at the purchase price determined in accordance with subsection (c) below. 

(c)       Purchase Price. The purchase price (“Purchase Price”)
for the Shares purchased by the Company or its assignee(s) under this Section shall be the Offered Price. If the Offered Price includes consideration other than cash, the cash equivalent value of the non-cash consideration shall be determined by the
Board of Directors of the Company in good faith. 
 (d)       Payment. Payment of the
Purchase Price shall be made, at the option of the Company or its assignee(s), in cash (by check), by cancellation of all or a portion of any outstanding indebtedness of the Holder to the Company (or, in the case of repurchase by an assignee, to the
assignee), or by any combination thereof within 30 days after receipt of the Notice or in the manner and at the times set forth in the Notice. 

(e)       Holder’s Right to Transfer. If all of the Shares proposed in the Notice
to be transferred to a given Proposed Transferee are not purchased by the Company and/or its assignee(s) as provided in this Section, then the Holder may sell or otherwise transfer such Shares to that Proposed Transferee at the Offered Price or at a
higher price, provided that such sale or other transfer is consummated within 120 days after the date of the Notice, that any such sale or other transfer is effected in accordance with any applicable securities laws and that the Proposed Transferee
agrees in writing that the provisions of this Section shall continue to apply to the Shares in the hands of such Proposed Transferee. If the Shares described in the Notice are not transferred to the Proposed Transferee within such period, a new
Notice shall be given to the Company, and the Company and/or its assignees shall again be offered the Right of First Refusal before any Shares held by the Holder may be sold or otherwise transferred. 

(f)       Exception for Certain Family Transfers. Anything to the contrary contained in
this Section notwithstanding, the transfer of any or all of the Shares during Optionee’s lifetime or on Optionee’s death by will or intestacy to Optionee’s immediate family or a trust for the benefit of Optionee’s immediate
family shall be exempt from the provisions of this Section. “Immediate Family” as used herein shall mean spouse, lineal descendant or antecedent, father, mother, brother or sister. In such case, the transferee or other
recipient shall receive and hold the Shares so transferred subject to the provisions of this Section, and there shall be no further transfer of such Shares except in accordance with the terms of this Section. 

(g)       Termination of Right of First Refusal. The Right of First Refusal shall
terminate as to any Shares upon the earlier of (i) first sale of Common Stock of the Company to the general public, or (ii) a Change in Control in which the successor corporation has equity securities that are publicly traded. 

6.       Tax Consultation. Optionee understands that Optionee may suffer adverse tax
consequences as a result of Optionee’s purchase or disposition of the Shares. Optionee represents that Optionee has consulted with any tax consultants Optionee deems advisable in connection with

  
 -2- 

 
the purchase or disposition of the Shares and that Optionee is not relying on the Company for any tax advice. 

7.       Restrictive Legends and Stop-Transfer Orders. 

(a) Legends. Optionee understands and agrees that the Company shall cause the legends set forth below or legends
substantially equivalent thereto, to be placed upon any certificate(s) evidencing ownership of the Shares together with any other legends that may be required by the Company or by state or federal securities laws: 

THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED,
OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THE SECURITIES UNDER SAID ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED. THIS CERTIFICATE MUST BE SURRENDERED TO THE
COMPANY OR ITS TRANSFER AGENT AS A CONDITION PRECEDENT TO THE SALE, PLEDGE OR OTHER TRANSFER OF ANY INTEREST IN ANY OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE. 

THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO RESTRICTIONS ON TRANSFER AS SET FORTH IN AN AGREEMENT BETWEEN THE
COMPANY AND THE REGISTERED HOLDER, OR HIS PREDECESSOR IN INTEREST, A COPY OF WHICH IS ON FILE AT THE PRINCIPAL OFFICE OF THE COMPANY. 

(b)       Stop-Transfer Notices. Optionee agrees that, in order to ensure compliance
with the restrictions referred to herein, the Company may issue appropriate “stop transfer” instructions to its transfer agent, if any, and that, if the Company transfers its own securities, it may make appropriate notations to the
same effect in its own records. 
 (c)       Refusal to Transfer. The Company shall
not be required (i) to transfer on its books any Shares that have been sold or otherwise transferred in violation of any of the provisions of this Exercise Notice or (ii) to treat as owner of such Shares or to accord the right to vote or
pay dividends to any purchaser or other transferee to whom such Shares shall have been so transferred. 

8.       Successors and Assigns. The Company may assign any of its rights under this
Exercise Notice to single or multiple assignees, and this Exercise Notice shall inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer herein set forth, this Exercise Notice shall be binding upon
Optionee and his or her heirs, executors, administrators, successors and assigns. 
 9.      
Interpretation. Any dispute regarding the interpretation of this Exercise Notice shall be submitted by Optionee or by the Company forthwith to the Administrator, which shall review such dispute at its next regular meeting. The resolution of
such a dispute by the Administrator shall be final and binding on all parties. 

  
 -3- 

 10.       Governing Law. This Exercise
Notice will be administered consistent with the requirements of applicable Delaware law relating to the issuance of stock and the consideration to be received therefor, and with the applicable requirements of the stock exchanges or other trading
systems on which the Shares are listed or entered for trading, in each case as determined by the Board. Except as otherwise provided in the preceding sentence, the provisions of this Exercise Notice and all claims or disputes arising out of our
based upon this Exercise Notice or relating to the subject matter hereof will be governed by and construed in accordance with the domestic substantive laws of the State of California without giving effect to any choice or conflict of laws provision
or rule that would cause the application of the domestic substantive laws of any other jurisdiction. 

11.       Entire Agreement. The Plan and Option Agreement are incorporated herein by
reference. This Exercise Notice, the Plan, the Option Agreement and the Investment Representation Statement constitute the entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior
undertakings and agreements of the Company and Optionee with respect to the subject matter hereof, and may not be modified adversely to Optionee’s interest except by means of a writing signed by the Company and Optionee. 

 

					
	 Submitted by:
	  		  	 Accepted by:

			
	 OPTIONEE
	  		  	 CARBYLAN THERAPEUTICS, INC.

			
	  
	  		  	  

	 Signature
	  		  	 By

			
	  
	  		  	
	 Print Name
	  		  	 Its

			
	 Address:
	  		  	 Address:

			
	  
	  		  	  

	  
	  		  	  

	  
	  		  	  

			
		  		  	  

		  		  	 Date Received

  
 -4- 

 EXHIBIT B 

INVESTMENT REPRESENTATION STATEMENT 
  

					
	 OPTIONEE
	  	:	  	
			
	 COMPANY
	  	:	  	 CARBYLAN THERAPEUTICS, INC.

			
	 SECURITY
	  	:	  	 COMMON STOCK

			
	 AMOUNT
	  	:	  	
			
	 DATE
	  	:	  	

 In connection with the purchase of the above-listed securities (“Securities”), the
undersigned Optionee represents to the Company the following: 
 (a)       Optionee is aware
of the Company’s business affairs and financial condition and has acquired sufficient information about the Company to reach an informed and knowledgeable decision to acquire the Securities. Optionee is acquiring these Securities for investment
for Optionee’s own account only and not with a view to, or for resale in connection with, any “distribution” thereof within the meaning of the Securities Act of 1933, as amended (the “Securities
Act”). 
 (b)       Optionee acknowledges and understands that the
Securities constitute “restricted securities” under the Securities Act and have not been registered under the Securities Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide
nature of Optionee’s investment intent as expressed herein. In this connection, Optionee understands that, in the view of the Securities and Exchange Commission, the statutory basis for such exemption may be unavailable if Optionee’s
representation was predicated solely upon a present intention to hold these Securities for the minimum capital gains period specified under tax statutes, for a deferred sale, for or until an increase or decrease in the market price of the
Securities, or for a period of one year or any other fixed period in the future. Optionee further understands that the Securities must be held indefinitely unless they are subsequently registered under the Securities Act or an exemption from such
registration is available. Optionee further acknowledges and understands that the Company is under no obligation to register the Securities. Optionee understands that the certificate evidencing the Securities will be imprinted with any legend
required under applicable state securities laws. 
 (c)       Optionee is familiar with the
provisions of Rule 701 and Rule 144, each promulgated under the Securities Act, which, in substance, permit limited public resale of “restricted securities” acquired, directly or indirectly from the issuer thereof, in a
non-public offering subject to the satisfaction of certain conditions. Rule 701 provides that if the issuer qualifies under Rule 701 at the time of the grant of the Option to Optionee, the exercise will be exempt from registration under
the Securities Act. In the event the Company becomes subject to the reporting requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, ninety (90) days thereafter (or such

 
longer period as any market stand-off agreement may require) the Securities exempt under Rule 701 may be resold, subject to the satisfaction of certain of the conditions specified by
Rule 144, including: (1) the resale being made through a broker in an unsolicited “broker’s transaction” or in transactions directly with a market maker (as said term is defined under the Securities Exchange Act of
1934); and, in the case of an affiliate, (2) the availability of certain public information about the Company, (3) the amount of Securities being sold during any three month period not exceeding the limitations specified in
Rule 144(e), and (4) the timely filing of a Form 144, if applicable. 
 In the event that the Company does not
qualify under Rule 701 at the time of grant of the Option, then the Securities may be resold in certain limited circumstances subject to the provisions of Rule 144. 

(d)       Optionee further understands that in the event all of the applicable requirements of
Rule 701 or 144 are not satisfied, registration under the Securities Act, compliance with Regulation A, or some other registration exemption will be required; and that, notwithstanding the fact that Rules 144 and 701 are not exclusive, the
Staff of the Securities and Exchange Commission has expressed its opinion that persons proposing to sell private placement securities other than in a registered offering and otherwise than pursuant to Rules 144 or 701 will have a substantial burden
of proof in establishing that an exemption from registration is available for such offers or sales, and that such persons and their respective brokers who participate in such transactions do so at their own risk. Optionee understands that no
assurances can be given that any such other registration exemption will be available in such event. 
  

			
	Signature of Optionee:
	
	  

		
	Date:	 	  

  
 -2- 

 EXHIBIT C-1 

CARBYLAN THERAPEUTICS, INC. 

2014 STOCK OPTION PLAN 

RESTRICTED STOCK PURCHASE AGREEMENT 

THIS AGREEMENT is made between
[                        ] (“Purchaser”) and Carbylan Therapeutics, Inc. (the
“Company”) or its assignees of rights hereunder as of
                            ,
            . 
 Unless otherwise defined herein, the
terms defined in the 2014 Stock Option Plan shall have the same defined meanings in this Agreement. 
 RECITALS 

A.       Pursuant to the exercise of the option granted to Purchaser under the
Plan and pursuant to the Option Agreement dated                         ,
            , by and between the Company and Purchaser with respect to such grant (the “Option”), which Plan and Option Agreement are hereby incorporated by
reference, Purchaser has elected to purchase                     of those shares of Common Stock which have not become vested under the
vesting schedule set forth in the Option Agreement (“Unvested Shares”). The Unvested Shares and the shares subject to the Option Agreement that have become vested are collectively referred to herein as the
“Shares.” 
 B.       As required by the Option
Agreement, as a condition to Purchaser’s election to exercise the Option, Purchaser must execute this Agreement, which sets forth the rights and obligations of the parties with respect to Shares acquired upon exercise of the Option. 

1.       Repurchase Option. 

(a)       If Purchaser’s status as a Service Provider is terminated for any reason,
including for death and Disability, the Company shall have the right and option for ninety (90) days from such date to purchase from Purchaser, or Purchaser’s personal representative, as the case may be, all of Purchaser’s Unvested
Shares as of the date of such termination at the lesser of the price paid by Purchaser for such Shares and the Fair Market Value of such Shares on the date of repurchase (the “Repurchase Option”). 

(b)       Upon the occurrence of such termination, the Company may exercise the Repurchase
Option by delivering personally or by registered mail, to Purchaser (or Purchaser’s transferee or legal representative, as the case may be) with a copy to the escrow agent described in Section 2 below, a notice in writing indicating the
Company’s intention to exercise the Repurchase Option AND, at the Company’s option, (i) by delivering to Purchaser (or Purchaser’s transferee or legal representative) a check in the amount of the aggregate repurchase price, or
(ii) by the Company canceling an amount of Purchaser’s indebtedness to the Company equal to the aggregate repurchase price, or (iii) by a combination of (i) and (ii) so that the combined payment and cancellation of

  
 -3- 

 
indebtedness equals such aggregate repurchase price. Upon delivery of such notice and payment of the aggregate repurchase price in any of the ways described above, the Company shall become the
legal and beneficial owner of the Unvested Shares being repurchased and the rights and interests therein or relating thereto, and the Company shall have the right to retain and transfer to its own name the number of Unvested Shares being repurchased
by the Company. 
 (c)       Whenever the Company shall have the right to repurchase Unvested
Shares hereunder, the Company may designate and assign one or more employees, officers, directors or stockholders of the Company or other persons or organizations to exercise all or a part of the Company’s Repurchase Option under this Agreement
and purchase all or a part of such Unvested Shares. 
 (d)       If the Company does not
elect to exercise the Repurchase Option conferred above by giving the requisite notice within ninety (90) days following the termination, the Repurchase Option shall terminate. 

(e)       The Repurchase Option shall terminate in accordance with the vesting schedule
contained in Purchaser’s Option Agreement. 
 2.       Transferability of the Shares;
Escrow. 
 (a)       Purchaser hereby authorizes and directs the Secretary of the
Company, or such other person designated by the Company, to transfer the Unvested Shares as to which the Repurchase Option has been exercised from Purchaser to the Company. 

(b)       To insure the availability for delivery of Purchaser’s Unvested Shares upon
repurchase by the Company pursuant to the Repurchase Option under Section 1, Purchaser hereby appoints the Secretary, or any other person designated by the Company as escrow agent (the “Escrow Agent”), as its
attorney-in-fact to sell, assign and transfer unto the Company, such Unvested Shares, if any, repurchased by the Company pursuant to the Repurchase Option and shall, upon execution of this Agreement, deliver and deposit with the Escrow Agent, the
share certificates representing the Unvested Shares, together with the stock assignment duly endorsed in blank, attached hereto as Exhibit C-2. The Unvested Shares and stock assignment shall be held by the Escrow Agent in escrow,
pursuant to the Joint Escrow Instructions of the Company and Purchaser attached as Exhibit C-3 hereto, until the Company exercises its Repurchase Option, until such Unvested Shares are vested, or until such time as this Agreement no
longer is in effect. Upon vesting of the Unvested Shares, the Escrow Agent shall promptly deliver to Purchaser the certificate or certificates representing such Shares in the Escrow Agent’s possession belonging to Purchaser, and the Escrow
Agent shall be discharged of all further obligations hereunder; provided, however, that the Escrow Agent shall nevertheless retain such certificate or certificates as Escrow Agent if so required pursuant to other restrictions imposed pursuant to
this Agreement. 
 (c)       The Company nor the Escrow Agent shall be liable for any act it
may do or omit to do with respect to holding the Shares in escrow and while acting in good faith and in the exercise of its judgment. 

(d)       Transfer or sale of the Shares is subject to restrictions on transfer imposed by any
applicable state and federal securities laws. Any transferee shall hold such Shares subject to all 

  
 -4- 

 
the provisions hereof and the Exercise Notice executed by Purchaser with respect to any Unvested Shares purchased by Purchaser and shall acknowledge the same by signing a copy of this Agreement.

 3.       Ownership, Voting Rights, Duties. This Agreement shall not affect in any
way the ownership, voting rights or other rights or duties of Purchaser, except as specifically provided herein. 

4.       Legends. The share certificate evidencing the Shares issued hereunder shall be
endorsed with the following legend (in addition to any legend required under applicable federal and state securities laws): 

THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN RESTRICTIONS UPON TRANSFER AND RIGHTS OF REPURCHASE AS SET
FORTH IN AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. 

5.       Notices. Notices required hereunder shall be given in person or by registered
mail to the address of Purchaser shown on the records of the Company, and to the Company at their respective principal executive offices. 

6.       Survival of Terms. This Agreement shall apply to and bind Purchaser and the
Company and their respective permitted assignees and transferees, heirs, legatees, executors, administrators and legal successors. 

7.       Section 83(b) Election. Purchaser hereby acknowledges that he or she has
been informed that, with respect to the exercise of an Option for Unvested Shares, an election (an “Election”) may be filed by Purchaser with the Internal Revenue Service, within thirty (30) days of the purchase of the
Shares, electing pursuant to Section 83(b) of the Code to be taxed currently on any difference between the purchase price of the Shares and their Fair Market Value on the date of purchase. Purchaser is strongly encouraged to seek the advice of
his or her own tax consultants in connection with the purchase of the Shares and the advisability of filing of an Election. A form of Election under Section 83(b) is attached hereto as Exhibit C-4 for reference. 

PURCHASER ACKNOWLEDGES THAT IT IS PURCHASER’S SOLE RESPONSIBILITY AND NOT THE COMPANY’S TO FILE TIMELY THE ELECTION
UNDER SECTION 83(b) OF THE CODE, EVEN IF PURCHASER REQUESTS THE COMPANY OR ITS REPRESENTATIVE TO MAKE THIS FILING ON PURCHASER’S BEHALF. 

8.       Representations. Purchaser has reviewed with his own tax advisors the federal,
state, local and foreign tax consequences of this investment and the transactions contemplated by this Agreement. Purchaser is relying solely on such advisors and not on any statements or representations of the Company or any of its agents.
Purchaser understands that Purchaser (and not the Company) shall be responsible for his own tax liability that may arise as a result of this investment or the transactions contemplated by this Agreement. 

  
 -5- 

 9.       Governing Law. This Agreement will
be administered consistent with the requirements of applicable Delaware law relating to the issuance of stock and the consideration to be received therefor, and with the applicable requirements of the stock exchanges or other trading systems on
which the Shares are listed or entered for trading, in each case as determined by the Board. Except as otherwise provided in the preceding sentence, the provisions of this Agreement and all claims or disputes arising out of our based upon this
Agreement or relating to the subject matter hereof will be governed by and construed in accordance with the domestic substantive laws of the State of California without giving effect to any choice or conflict of laws provision or rule that would
cause the application of the domestic substantive laws of any other jurisdiction. 
 Purchaser represents that he or she has
read this Agreement and is familiar with its terms and provisions. Purchaser hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Board upon any questions arising under this Agreement. 

IN WITNESS WHEREOF, this Agreement is deemed made as of the date first set forth above. 

 

					
	 OPTIONEE
	  		  	 CARBYLAN THERAPEUTICS, INC.

			
	  
	  		  	  

	 Signature
	  		  	 By

			
	  
	  		  	  

	 Print Name
	  		  	 Title

			
	 Residence Address:
	  		  	
	  
	  		  	
	  
	  		  	
			
	
Dated:                        
                                 ,
                
	  		  	

  
 -6- 

 EXHIBIT C-2 

ASSIGNMENT SEPARATE FROM CERTIFICATE 

FOR VALUE RECEIVED I,
                                    , hereby sell, assign and
transfer unto Carbylan Therapeutics, Inc.
                                (       
         ) shares of the Common Stock of Carbylan Therapeutics, Inc. standing in my name of the books of said corporation represented by Certificate
No.              herewith and do hereby irrevocably constitute and
appoint                          to transfer the said stock on the books of the within named corporation with full
power of substitution in the premises. 
 This Stock Assignment may be used only in accordance with the Restricted Stock
Purchase Agreement between Carbylan Therapeutics, Inc. and the undersigned dated                     ,
            (the “Agreement”). 
  

									
	Dated:	 	                                      
  ,         	 		 	Signature:	 	 

  
  
  

INSTRUCTIONS: Please do not fill in any blanks other than the signature line. The purpose of this assignment is to enable the
Company to exercise its “repurchase option,” as set forth in the Agreement, without requiring additional signatures on the part of Purchaser. 

 EXHIBIT C-3 

JOINT ESCROW INSTRUCTIONS 

                       
     ,              
 Corporate Secretary 

Carbylan Therapeutics, Inc. 
 3181 Porter Drive 

Palo Alto, CA 94306 
  

Dear                         :

 As Escrow Agent for both Carbylan Therapeutics, Inc. (the “Company”), and the undersigned
purchaser of stock of the Company (“Purchaser”), you are hereby authorized and directed to hold the documents delivered to you pursuant to the terms of that certain Restricted Stock Purchase Agreement (the
“Agreement”) between the Company and the undersigned, in accordance with the following instructions: 

1.       In the event the Company and/or any assignee of the Company (referred to
collectively for convenience herein as the “Company”) exercises the Company’s repurchase option set forth in the Agreement, the Company shall give to Purchaser and you a written notice specifying the number of shares of
stock to be purchased, the purchase price, and the time for a closing hereunder at the principal office of the Company. Purchaser and the Company hereby irrevocably authorize and direct you to close the transaction contemplated by such notice in
accordance with the terms of said notice. 
 2.       At the closing, you are
directed (a) to date the stock assignments necessary for the transfer in question, (b) to fill in the number of shares being transferred, and (c) to deliver the stock assignments, together with the certificate evidencing the shares of
stock to be transferred, to the Company or its assignee, against the simultaneous delivery to you of the purchase price (by cash, a check, or some combination thereof) for the number of shares of stock being purchased pursuant to the exercise of the
Company’s repurchase option. 
 3.       Purchaser irrevocably authorizes the Company to
deposit with you any certificates evidencing shares of stock to be held by you hereunder and any additions and substitutions to said shares as defined in the Agreement. Purchaser does hereby irrevocably constitute and appoint you as Purchaser’s
attorney-in-fact and agent for the term of this escrow to execute with respect to such securities all documents necessary or appropriate to make such securities negotiable and to complete any transaction herein contemplated, including but not
limited to the filing with any applicable state blue sky authority of any required applications for consent to, or notice of transfer of, the securities. Subject to the provisions of this paragraph 3, Purchaser shall exercise all rights and
privileges of a stockholder of the Company while the stock is held by you. 
 4.       Upon
written request of Purchaser, but no more than once per calendar year, unless the Company’s repurchase option has been exercised, you will deliver to Purchaser a certificate or 

 
certificates representing so many shares of stock as are not then subject to the Company’s repurchase option. Within 120 days after cessation of Purchaser’s continuous employment by or
services to the Company, or any parent or subsidiary of the Company, you will deliver to Purchaser a certificate or certificates representing the aggregate number of shares held or issued pursuant to the Agreement and not purchased by the Company or
its assignees pursuant to exercise of the Company’s repurchase option. 
 5.       If at
the time of termination of this escrow you should have in your possession any documents, securities, or other property belonging to Purchaser, you shall deliver all of the same to Purchaser and shall be discharged of all further obligations
hereunder. 
 6.       Your duties hereunder may be altered, amended, modified or revoked only
by a writing signed by all of the parties hereto. 
 7.       You shall be obligated only for
the performance of such duties as are specifically set forth herein and may rely and shall be protected in relying or refraining from acting on any instrument reasonably believed by you to be genuine and to have been signed or presented by the
proper party or parties. You shall not be personally liable for any act you may do or omit to do hereunder as Escrow Agent or as attorney-in-fact for Purchaser while acting in good faith, and any act done or omitted by you pursuant to the advice of
your own attorneys shall be conclusive evidence of such good faith. 
 8.        You are
hereby expressly authorized to disregard any and all warnings given by any of the parties hereto or by any other person or corporation, excepting only orders or process of courts of law and are hereby expressly authorized to comply with and obey
orders, judgments or decrees of any court. In case you obey or comply with any such order, judgment or decree, you shall not be liable to any of the parties hereto or to any other person, firm or corporation by reason of such compliance,
notwithstanding any such order, judgment or decree being subsequently reversed, modified, annulled, set aside, vacated or found to have been entered without jurisdiction. 

9.        You shall not be liable in any respect on account of the identity, authorities or
rights of the parties executing or delivering or purporting to execute or deliver the Agreement or any documents or papers deposited or called for hereunder. 

10.       You shall not be liable for the outlawing of any rights under the Statute of
Limitations with respect to these Joint Escrow Instructions or any documents deposited with you. 

11.       You shall be entitled to employ such legal counsel and other experts as you may deem
necessary properly to advise you in connection with your obligations hereunder, may rely upon the advice of such counsel, and may pay such counsel reasonable compensation therefor. 

12.       Your responsibilities as Escrow Agent hereunder shall terminate if you shall cease to
be an officer or agent of the Company or if you shall resign by written notice to each party. In the event of any such termination, the Company shall appoint a successor Escrow Agent. 

13.       If you reasonably require other or further instruments in connection with these Joint
Escrow Instructions or obligations in respect hereto, the necessary parties hereto shall join in furnishing such instruments. 

  
 -2- 

 14.       It is understood and agreed that should
any dispute arise with respect to the delivery and/or ownership or right of possession of the securities held by you hereunder, you are authorized and directed to retain in your possession without liability to anyone all or any part of said
securities until such disputes shall have been settled either by mutual written agreement of the parties concerned or by a final order, decree or judgment of a court of competent jurisdiction after the time for appeal has expired and no appeal has
been perfected, but you shall be under no duty whatsoever to institute or defend any such proceedings. 

15.       Any notice required or permitted hereunder shall be given in writing and shall be
deemed effectively given upon personal delivery or upon deposit in the United States Post Office, by registered or certified mail with postage and fees prepaid, addressed to each of the other parties thereunto entitled at the following addresses or
at such other addresses as a party may designate by ten days’ advance written notice to each of the other parties hereto. 

16.       By signing these Joint Escrow Instructions, you become a party hereto only for the
purpose of said Joint Escrow Instructions; you do not become a party to the Agreement. 

17.       This instrument shall be binding upon and inure to the benefit of the parties hereto,
and their respective successors and permitted assigns. 
 18.       These Joint Escrow
Instructions will be administered consistent with the requirements of applicable Delaware law relating to the issuance of stock and the consideration to be received therefor, and with the applicable requirements of the stock exchanges or other
trading systems on which the Shares are listed or entered for trading, in each case as determined by the Board. Except as otherwise provided in the preceding sentence, the provisions of these Joint Escrow Instructions and all claims or disputes
arising out of our based upon these Joint Escrow Instructions or relating to the subject matter hereof will be governed by and construed in accordance with the domestic substantive laws of the State of California without giving effect to any choice
or conflict of laws provision or rule that would cause the application of the domestic substantive laws of any other jurisdiction. 
  

					
	 PURCHASER
	  		  	 CARBYLAN THERAPEUTICS, INC.

			
	  
	  		  	  

	 Signature
	  		  	 By

			
	  
	  		  	  

	 Print Name
	  		  	 Title

			
	 Residence Address:
	  		  	
	  
	  		  	
	  
	  		  	

  
 -3- 

					
	ESCROW AGENT	  		  	
			
	  
	  		  	
	Corporate Secretary	  		  	
			
	Dated:
                                         
               ,            	  		  	

  
 -4- 

 EXHIBIT C-4 

ELECTION UNDER SECTION 83(b) 

OF THE INTERNAL REVENUE CODE OF 1986 

The undersigned taxpayer hereby elects, pursuant to Section 83(b) of the Internal Revenue Code of 1986, as amended, to include in
taxpayer’s gross income or alternative minimum taxable income, as the case may be, for the current taxable year the amount of any compensation taxable to taxpayer in connection with taxpayer’s receipt of the property described below 

 

	1.	 The name, address, taxpayer identification number and taxable year of the undersigned are as follows: 

 

							
	
Name of Taxpayer:                        
                                         
                  
	  		  	
			
	
Name of Spouse:                         
                                         
                    
	  		  	
				
	 Address:
	  	  
	  		  	
		  	  
	  		  	
			
	
Identification No. of Taxpayer:                     
                                         
   
	  		  	
			
	
Identification No. of Spouse:                      
                                         
      
	  		  	
			
	 Taxable Year:                 
	  		  	

  

	2.	 The property with respect to which the election is made is described as follows:
                     shares (the “Shares”) of the Common Stock of Carbylan Therapeutics, Inc. (the
“Company”). 

  

	3.	 The date on which the property was transferred
is:                            . 

 

	4.	 The property is subject to the following restrictions: 

  

	    	 The Shares may not be transferred and are subject to forfeiture under the terms of an agreement between the taxpayer and the Company. These
restrictions lapse upon the satisfaction of certain conditions contained in such agreement. 

  

	5.	 The fair market value at the time of transfer, determined without regard to any restriction other than a restriction which by its terms will never
lapse, of such property is: $                            . 

 

	6.	 The amount (if any) paid for such property is:
$                            . 

The undersigned has submitted a copy of this statement to the person for whom the services were performed in connection with the
undersigned’s receipt of the above-described property. The transferee of such property is the person performing the services in connection with the transfer of said property. 

The undersigned understands that the foregoing election may not be revoked except with the consent of the Commissioner. 

  

							
	 Dated:
	  	  
	  		  	  

		  		  		  	 Taxpayer

	
	 The undersigned spouse of taxpayer joins in this election.

				
	 Dated:
	  	 ______________________
	  		  	  

		  		  		  	 Spouse of Taxpayer

  
 -2-EX-10.4

 EXHIBIT 10.4 

TECHNOLOGY LICENSE AGREEMENT 
 This
Technology License Agreement is made and entered into this 15th day of November, 2012 (the “Effective Date”), by and between Carbylan Biosurgery, Inc., a Delaware corporation, having its principal place of business at 3181 Porter Drive,
Palo Alto, California, 94304 (hereinafter, “Carbylan”) and Shanghai Jingfeng Pharmaceutical Co., Ltd., a Chinese limited liability company having its principal place of business at No. 50, Luoxin Road, Baoshan District, Shanghai, PRC,
201908 (hereinafter, “Jingfeng” or “Licensee”). 
 WITNESSETH: 

WHEREAS, Carbylan and Jingfeng (hereinafter referred to individually as a “Party” or collectively as the “Parties”) executed a
Mutual Non-Disclosure Agreement, dated as of November 21, 2011 (hereinafter referred to as the “NDA”), as well as a Technology Development and License Term Sheet, dated September 21, 2012 (the “Term Sheet”), which
contains the terms and conditions pursuant to which Carbylan would grant Jingfeng an exclusive, royalty-bearing license under the Patents (as hereinafter defined) and Know-How (as hereinafter defined) to develop, manufacture and market the Compound
in the Territory (as hereinafter defined); 
 WHEREAS, Jingfeng desires to pursue the commercialization of Compound in the Territory and desires to
obtain from Carbylan the exclusive right and license necessary to do so, and Carbylan desires to grant such rights and licenses, all under the terms and conditions set forth in this Agreement. 

NOW, THEREFORE, in consideration of the mutual covenants, terms and conditions contained herein, the Parties hereto agree as follows: 

 

	1.	Definitions 

 As used in this Agreement, the following terms (the singular may include the plural and vice
versa) shall have the following meanings: 
  

	 	1.1	“Affiliates” shall mean, with respect to a Party, any person or entity directly or indirectly controlling, controlled by, or under common control with such Party. For this purpose, “control”
shall mean the power whether or not normally exercised, to direct the management and affairs of another corporation or other entity, directly or indirectly, whether through the ownership of voting securities, by contract, or otherwise. In case
of a corporation, the direct or indirect ownership of fifty percent (50%) or more of its outstanding voting securities shall in any case be deemed to confer “control”. 

 

	 	1.2	“Anti-Corruption Laws” shall mean all applicable laws, regulations, orders, judicial decisions, conventions and international financial institution rules regarding corruption, bribery, ethical business
conduct, money laundering, political contributions, gifts and gratuities, or lawful expenses to public officials and private persons, agency relationships, commissions, lobbying, books and records, and financial controls. 

 

	 	1.3	“Applicable Laws” shall mean any and all laws, rules, regulations, directives, and guidances of any governmental authority in the Territory pertaining to the development, manufacture, extrusion, packaging,
labeling, storage, marketing, sale, import, export, distribution or intended use of the Compound and/or Licensed Product, as amended from time-to-time. 

  

	 	1.4	 “Business Day” shall mean any day on which commercial banks are open for 

  

	 	
business in the United States and the People’s Republic of China. 

  

	 	1.5	“Commercially Reasonable Efforts” shall mean the performance of obligations or tasks in a continuous, sustained manner consistent with the reasonable best practices of the industry for marketing, promotion,
sale and distribution of a product having similar technical and regulatory factors and similar market potential, profit potential and strategic value, and that is at a similar stage in its product life cycle. 

 

	 	1.6	“Compound” or “Compounds” shall mean Hydros-TA, together with any modification or improvement thereto that are (a) hyaluronan-based product combined with a corticosteroid and (b) developed
by, licensed to, or otherwise Controlled by Carbylan and claimed under any Patent. For the purposes of this Agreement, a modification or an improvement shall mean any invention, discovery, modification or improvement, whether patentable or not,
which can (A) be employed to reduce manufacturing costs, improve the performance, or broaden the applicability or range of uses of a Compound and/or Licensed Product within the Field; (B) create a wholly new product. 

 

	 	1.7	“Control” means, with respect to any patent applications, patents, material, know-how or other information, that a Party owns or has a license thereto and has the ability to grant to the other Party access
and/or a license thereto as provided herein without violating the terms of any agreement or other arrangement with any Third Party and without incurring any obligations, including payment of royalties, to that Third Party. 

 

	 	1.8	“Field” shall mean all human and veterinary uses, including, but not limited to, prophylactic and therapeutic treatment of human or veterinary diseases or diagnosis of human or veterinary diseases.

  

	 	1.9	“FCPA” shall mean the U.S. Foreign Corrupt Practices Act (15 U.S.C. Section 78dd-1, et seq.) as amended. 

  

	 	1.10	“GMPs” shall mean Good Manufacturing Practices, as to Carbylan, as enforced by the U.S. Food & Drug Administration and, as to Jingfeng, as enforced by the relevant regulatory authority in the
Territory. 

  

	 	1.11	“Gross Sales Proceeds” shall mean all monies and all other consideration (e.g., stock or “in-kind” property) received by Jingfeng, its Affiliates, or Sublicensees from the sale of Licensed Products,
notwithstanding sums actually paid or credited thereby such as: (i) sales, value added, use or other taxes directly imposed with reference to particular sales; (ii) amounts allowed or credited on returns (not in excess of the selling price
of such Licensed Product) on account of rejection, recalls or failure of the Licensed Product; or (iii) amounts allowed as customary chargeback payments and rebates. Gross Sales Proceeds shall be calculated in accordance with generally accepted
international financial reporting standards or Chinese GAAP, whichever is adopted by Jingfeng in its accounting system.

  

	 	1.12	 “Know-How” shall mean all information, data and trade secrets Controlled by Carbylan or its Affiliates as of the Effective Date or during the Term of
this Agreement in the Territory relating to the Compound and/or the Licensed Products to the extent necessary or reasonably useful to develop for the purpose of obtaining Regulatory Approval of, to manufacture or to commercialize the Licensed
Product, whether protected by intellectual property rights or not, including but not limited to (A) materials, documents, data, notes, memoranda, research briefs, articles, correspondence, processes, specifications, formulae, procedures,
techniques, practices, quality control processes and procedures, designs, apparatus, manufacturing processes and data, and instructions of, and scientific, analytical and technical data and studies for, the efficacy, pharmacology, toxicology,
synthesis, 

  
 2 

	 	
pharmaceutical processing and manufacture, packaging, storage and transportation of the Compound and/or Licensed Products, (B) non-clinical, pre-clinical, and clinical data and studies,
including clinical trial design and protocols, knowledge, technology, written and oral rectifications of data relating to the Compound and/or Licensed Products which are owned or Controlled by Carbylan or its Affiliates now and/or in the future and
may be necessary or reasonably useful to enable Jingfeng to obtain the Regulatory Approval, (C) any and all submissions to, responses, requests and/or comments from, and correspondence with the U.S. Food & Drug Administration
(“FDA”) and/or any analogous regulatory authority outside the United States, and (D) other intellectual property rights with respect to any invention, discovery, use, modification or improvement arising out of or relating to the
technology described in the Patents, in each case irrespective of whether such technology is (i) developed inside or outside the Territory, (ii) performed or in existence as of the Effective Date or subsequent thereto, (iii) in draft
or final form, and (iv) the subject of a patent application, patent or other right inside or outside of the Territory, in each case of (A)-(D) above, Controlled by Carbylan or its Affiliates as of the Effective Date or during the
Term of this Agreement in the Territory relating to the Compound and/or the Licensed Products to the extent necessary or reasonably useful to develop for the purpose of obtaining Regulatory Approval of, to manufacture or to commercialize the
Licensed Product. For clarity, Know-How shall exclude Patents. 

  

	 	1.13	“Licensed Products” shall mean human and veterinary pharmaceutical products containing the Compound in any form. 

  

	 	1.14	“Licensed Technology” shall mean the (A) Patents; (B) Know-How; and (C) Trademarks. 

  

	 	1.15	“Patents” shall mean: (a) the patents and patent applications as shown in Appendix I hereto and (b) any other patents and patent applications necessary or reasonably useful for the manufacture, use
or sale of the Compounds and/or Licensed Products that are Controlled by Carbylan or its Affiliates as of the Effective Date or during the Term of the Agreement in the Territory, in each case including (i) any and all divisionals,
continuations, and such claims of continuations-in-part as are entitled to claim priority to such patents and applications, and all reissues, reexaminations, extensions, and any letter patents issued thereon; and (ii) any and all corresponding
or counterpart filings with respect to (i) above as and when made in each country included in the Territory, including any and all divisionals, continuations, and such claims of continuations-in-part as are entitled to claim priority to such
patents and applications, and all reissues, reexaminations, extensions and any letter patents issued thereon. 

  

	 	1.16	“Person” shall mean any natural person or any corporation, partnership, limited liability company, business association, joint venture or other entity. 

 

	 	1.17	“Public Official or Entity” shall mean (i) any officer, employee, agent, representative, department, agency, de facto official, corporate entity, instrumentality or subdivision of any government, military
or international organization, including, but not limited to, any state-owned or affiliated company or hospital, or (ii) any candidate for political office, any political party or any official of a political party. 

 

	 	1.18	“Regulatory Approval” shall mean, with respect to a country or administrative region in the Territory, approval by the applicable health authorities necessary to conduct clinical trials and/or to manufacture
and market the Licensed Products in such country or administrative region, including pricing and reimbursement approval. 

  

	 	1.19	 “SDN” shall mean Specially Designated Nationals and Blocked Persons as 

  
 3 

	 	
designated by the U.S. Treasury Department’s Office of Foreign Assets Control. 

  

	 	1.20	“Sublicensees” shall mean any other person or entity to which Jingfeng will grant a sublicense in accordance with Section 2.2 hereof. 

 

	 	1.21	“Territory” shall mean the Greater China Region, which consists of the People’s Republic of China (“PRC”), Taiwan, Hong Kong and Macau. 

 

	 	1.22	“Third Party” shall mean any person, entity, company or organization; not including, however, the Parties or their respective Affiliates. 

 

	 	1.23	“Trademark” shall mean any trademark, trade names, service mark, logo and/or other commercial symbols either listed in Appendix II below or which Carbylan or its Affiliates Controls as of the Effective Date or
during the Term of the Agreement in the Territory and designated by Carbylan or its Affiliate for use with a Licensed Product. 

  

	 	1.24	“U.S.” shall mean the United States of America, including all possessions and territories thereof. 

  

	 	1.25	“U.S. Export Control Laws” shall mean all applicable U.S. laws and regulations relating to the export or re-export of commodities, technologies, or services, including, but not limited to, the Export
Administration Act of 1979, 24 U.S.C. §§ 2401-2420, the International Emergency Economic Powers Act, 50 U.S.C. §§ 1701-1706, the Trading with the Enemy Act, 50 U.S.C. §§ 1 et. seq., the Arms Export Control
Act, 22 U.S.C. §§ 2778 and 2779, and the International Boycott Provisions of Section 999 of the U.S. Internal Revenue Code of 1986. 

  

	2.	Grant of Licenses; Extension of Territory 

  

	 	2.1	License. Subject to the terms, conditions and provisions of this Agreement, Carbylan hereby grants to Jingfeng, during the Term of this Agreement, an exclusive right and license (with the right to sublicense
solely as provided in Section 2.2) under the Licensed Technology solely to the extent necessary for Jingfeng to make, have made, use, have used, market, have marketed, import, have imported, distribute, have distributed, sell and have sold the
Compound and Licensed Products in the Field in the Territory. 

  

	 	2.2	Sublicense. Jingfeng shall have the right to grant sublicenses of the license granted under Section 2.1; provided however, that Jingfeng shall remain the registered sponsor for the Licensed Products with the
Regulatory Authority in the Territory and Jingfeng shall not transfer such sponsorship without the prior written consent of Carbylan. Any sublicense granted by Jingfeng shall be subject to the same terms and conditions of this Agreement except that
Sublicensees shall be prohibited from granting further licenses. No sublicense shall relieve Jingfeng of any of its obligations under this Agreement. Jingfeng agrees to forward to Carbylan a complete and accurate copy and translation thereof written
in the English language and original language (if written in a language other than the English language) of each sublicense agreement it enters into prior to its execution for Carbylan’s review and approval. Jingfeng agrees to forward to
Carbylan a fully executed copy and translation thereof written in the English language (if written in a language other than the English language) of each sublicense agreement. Upon the termination of this Agreement for any cause, any and all
existing sublicenses hereunder shall thereupon automatically terminate. Such termination rights shall be made a condition of any sublicense granted by Jingfeng. 

  

	 	2.3	 Subcontract. Jingfeng and its Affiliates shall have the right to appoint subcontractors

  
 4 

	 	
(including distributors and/or sales agents) in the Territory for the commercialization of Licensed Products, and grant sublicenses under the license granted to it under Section 2.1 in
connection therewith. Jingfeng shall be primarily responsible for the actions and omissions of such subcontractors and the performance of the obligations hereunder. For the purpose of this Section 2.4, “distributors” and
“sales agents” shall include all parties appointed by Jingfeng or its Affiliates to market and sell the Licensed Products, in circumstances where such parties do not require a sublicense under the Patents to carry out such marketing and
sale. 

  

	 	2.4	Carbylan Covenant. Carbylan covenants that neither Carbylan nor any of its Affiliates will develop, manufacture, use, distribute, market, import or sell the Compounds or Licensed Products in the Territory during
the Term of this Agreement. Carbylan further covenants that neither Carbylan nor any of its Affiliates will, during the Term of this Agreement, grant a license to any Affiliate or any other party to develop, have developed, manufacture, have
manufactured, import, use, have used, distributed, have distributed, market, have marketed, sell and have sold the Compounds or Licensed Products in the Territory under the Patents and Know-How. 

 

	 	2.5	Jingfeng Covenant. Jingfeng covenants that neither Jingfeng nor any of its Affiliates will develop, manufacture, use, distribute, market, import or sell the Compounds or Licensed Products outside the
Territory. The Parties acknowledge and agree that the proceeding covenant will not apply to any Affiliate of Jingfeng that becomes an Affiliate after the Effective Date with respect to any Compound or Licensed Product developed and/or
commercialized by such Affiliate before it becomes an Affiliate of Jingfeng. Jingfeng further covenants that neither Jingfeng nor any of its Affiliates will grant a license to any Affiliate or any other party to develop, have developed, manufacture,
have manufactured, import, use, have used, distributed, have distributed, market, have marketed, sell and have sold the Compounds or Licensed Products outside the Territory. 

 

	 	2.6	Extension of Territory. Carbylan agrees to provide prompt notice to Jingfeng at any time it receives an inquiry or offer, whether oral or written, from a third party for the grant of rights with respect to the
commercialization, manufacture, sale and/or import of the Compound and/or a Licensed Product in [*]. In connection therewith, Carbylan further agrees to negotiate in good faith with Jingfeng, on a non-exclusive basis, the terms of a license grant
for such extension of the Territory. For the avoidance of doubt, (a) [*] shall be deemed to exclude [*] and [*] and (b) this Section 2.6 shall not apply to any transaction in which Carbylan would grant to a Third Party the right to
manufacture, develop or commercialize Licensed Products throughout [*], other than in the Territory. 

  

	3.	Development of the Licensed Products in the Territory; Regulatory Support 

  

	 	3.1	Development Plan. Carbylan acknowledges and agrees that Jingfeng shall have sole right to develop, commercialize, manufacture, import and sell the Licensed Products in the Field in the Territory, subject to
applicable regulatory approvals. Jingfeng shall conduct the development of the Licensed Product for Regulatory Approval solely in accordance with a development plan (the “Development Plan”) to be agreed upon by the Parties as soon as
practicable after the Effective Date. Any modification or change to the Development Plan shall be mutually agreed upon by the Parties in writing. 

  

	 	3.2	Manufacture and Supply.  

  

	 	(a)	Notwithstanding the foregoing, the Parties agree that Jingfeng will be responsible for the manufacture and supply of the Compound and 

 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 5 

	 	
Licensed Product for commercial sale in the Territory, except that: (i) Jingfeng shall have the right to purchase from Carbylan, [*] quantities of Compound solely to conduct its activities
under the Development Plan to support the Regulatory Approval of the Licensed Products in the Territory and not for commercial sale, and Carbylan agrees to supply such Compound from its manufacturer in the U.S., or, as the Parties may agree, any
non-U.S. manufacturer engaged by Carbylan; and (ii) Jingfeng shall have the right to purchase from Carbylan Licensed Product in quantities to be agreed upon by the Parties for sale in Taiwan, Hong Kong and Macau if Jingfeng obtains the
Regulatory Approval to do so, in which case the Parties shall negotiate in good faith a supply agreement governing such commercial supply of Licensed Products by Carbylan to Jingfeng. 

 

	 	(b)	In the event Carbylan supplies Jingfeng with the Compound pursuant to Section 3.2(a) above, Carbylan shall provide Jingfeng with such quantities of the Compound, with matching placebo, from the GMP batches
manufactured by Carbylan for its own clinical development activities, for use solely as reference materials for GMP clinical materials manufactured by Jingfeng for clinical trials in the Territory. Carbylan hereby confirms that all quantities of the
Compound delivered to Jingfeng pursuant to this Section 3.2 shall be manufactured in compliance with U.S. GMPs, and the quality of such Compound shall be certified by Carbylan’s quality control (QC) department. 

 

	 	(c)	In the event Carbylan is enjoined or otherwise prevented from supplying Jingfeng with the Compound and/or Licensed Product in accordance with Section 3.2(a), Carbylan shall within [*] notify Jingfeng of such
enjoinment or failure and shall cause a mutually-agreed Affiliate, contractor or non-U.S. manufacturer to supply such quantities of Compound and/or Licensed Product [*] within [*] of such enjoinment or failure, manufactured in compliance with GMPs
and certified by Carbylan’s QC department. 

  

	 	3.3	Development Activities. As between Carbylan and Jingfeng, Jingfeng shall be responsible for the management and funding of all development activities, regulatory submissions and Regulatory Approvals for the
Licensed Products in the Territory, pursuant to the Development Plan. If Jingfeng reasonably foresees or becomes aware of any delay of [*] or more in the actual development of the Products as compared with the timing set forth in the Development
Plan or any later modification thereof, Jingfeng shall promptly inform Carbylan of such delay in writing.  

  

	 	3.4	Regulatory and Commercial Launch Diligence Obligations. 

  

	 	(a)	Notwithstanding Section 3.3, Jingfeng agrees to use diligent efforts to launch and commercialize the Licensed Products in the Territory subject to receipt of applicable Regulatory Approvals. 

 

	 	(b)	Jingfeng agrees to submit all requisite materials to the appropriate regulatory authorities within [*] after the Effective Date for obtaining Regulatory Approval to conduct the first human clinical trial in the
Territory relating to at least one (1) Licensed Product (the “Initial Submission”), except that such timeline shall be extended to the extent the delay is caused by Carbylan not fulfilling its obligations under Article 4 below, in
which event Jingfeng shall not be deemed to be in default 

  

 

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 6 

	 	
under this Section 3.4(b) under the original timeline and the Parties further agree to cooperate to effect the Initial Submission as expeditiously as possible pursuant to the terms of this
Agreement. 

  

	 	(c)	Jingfeng shall develop (in accordance with the Development Plan) and register the Licensed Products in the Territory with the appropriate authorities on its sole responsibility. 

 

	 	3.5	Regulatory Progress Reports and Materials. In connection with the preparation of the documentation for Regulatory Approvals in the Territory, Jingfeng shall provide to Carbylan the following: 

 

	 	(a)	Jingfeng shall provide on a regular basis, but no less frequently than [*], such progress reports, technical information, regulatory documentation and clinical data generated by or on behalf of Jingfeng, as shall be
agreed in the Development Plan. [*] shall also include a current list of all of Jingfeng’s subcontractors and Sublicensees in the Territory. Carbylan shall have the right to use and reference such reports, information, documentation and data
for the development, manufacture and commercialization of the Licensed Products outside the Territory. 

  

	 	(b)	Jingfeng also agrees to have meetings with Carbylan (which may be telephonic) in a timely manner upon Carbylan’s reasonable request, at least [*], in order to report on the progress in the development of Licensed
Products in the Territory.

  

	 	(c)	For the avoidance of doubt, if any application is filed, or submission is made, with the competent authorities in the Territory in connection with the Regulatory Approval process, Jingfeng shall provide Carbylan with an
English summary of all materials submitted to such authorities (including any amendments thereto).

  

	 	(d)	Jingfeng shall promptly inform Carbylan of the Initial Submission, any material regulatory development, and any Regulatory Approval in any country or administrative regions in the Territory, and send to Carbylan a copy
of any correspondence, approval letter and/or confirmation with the Regulatory Authority in connection therewith, along with an English translation thereof.

  

	 	3.6	Records and Audit. Jingfeng agrees to keep in an accurate and complete manner, for a period of [*] following the final payment made to Carbylan pursuant to the terms of this Agreement, such documents and records
to the extent necessary to verify any report required under this Agreement or the activities of Jingfeng, its Affiliates and its Sublicensees under this Agreement. Upon [*] prior written notice by Carbylan, Jingfeng agrees to permit such records to
be examined from time to time, but not more frequently than [*], such examination to be made [*] by an auditor appointed by Carbylan. In addition, Carbylan (or its designee) shall be entitled to inspect and examine any manufacturing and/or other
facilities where the Compound and/or Licensed Products are manufactured, stored or sold. For each Sublicensee, distributor or sales agent of Jingfeng, Jingfeng shall obtain such audit rights for Carbylan. 

 

	 	3.7	Compliance with Law.  

  

	 	(a)	Jingfeng shall comply with all Applicable Laws pertaining to the use, import, export, transport, handling, storage, distribution, sales, and 

 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 7 

	 	
marketing, of the Compound and/or Licensed Products or otherwise pertaining to performance by Jingfeng of its obligations under this Agreement, including the maintenance of ongoing quality
assurance and testing procedures to comply with applicable regulatory requirements. Jingfeng shall maintain distribution records as required by regulatory requirements that are applicable to the Territory. Not more often than [*] and only with [*]
advance written notice, unless otherwise required by applicable laws or regulations or otherwise specified under this Agreement, Carbylan shall have the right to audit Jingfeng’s quality system and records related to Compound and/or Licensed
Products in the Territory. Jingfeng shall notify Carbylan promptly in writing of any changes in such laws and regulations in the Territory. Jingfeng shall promote Compound and/or Licensed Products only for their approved indications.

  

	 	(b)	Jingfeng agrees, in its performance of this Agreement, to comply with all applicable law, including the FCPA and U.S. Export Control Laws (in each case, to the extent such laws are applicable to Jingfeng) and
Anti-Corruption Laws in the Territory. Jingfeng further agrees to comply with the FCPA Guidelines as set forth in Appendix III. 

  

	 	(c)	Jingfeng represents and warrants that it is not identified on the List of Specially Designated Nationals & Blocked Persons (“SDNs”) as designated by the U.S. Treasury Department’s Office of
Foreign Assets Control. In connection with this Agreement, Jingfeng shall not sell any Licensed Product or engage in any other transaction in, to, or with (i) any of the following countries: Cuba, Iran, Sudan, North Korea, or Syria, or any
other country that becomes subject to sanctions imposed by the U.S. Government, or (ii) any individual or entity that is listed in the following: (A) List of Specially Designated Nationals & Blocked Persons, Office of Foreign
Assets Control, U.S. Treasury Department; (B) List of Debarred Parties, Directorate of Defense Trade Controls, U.S. State Department; (C) Denied Persons List, Bureau of Industry and Security, U.S. Department of Commerce; (D) Entity
List, Bureau of Industry and Security, U.S. Department of Commerce; (E) Unverified List, Bureau of Industry and Security, U.S. Department of Commerce; or (F) the Palestinian Legislative Counsel (PLC) List, Office of Foreign Assets Control,
U.S. Treasury Department. Jingfeng agrees that it will notify Carbylan promptly upon the occurrence of any event that would breach this covenant or render this representation and warranty incorrect. 

 

	 	(d)	Jingfeng represents and warrants that it shall take no action that would cause Carbylan to be in violation of the FCPA, U.S. Export Control Laws or any other applicable Anti-Corruption Laws in the Territory. Further,
Jingfeng shall immediately notify Carbylan if Jingfeng has any information or suspicion that there may be a violation of the FCPA or any other Anti-Corruption Law in connection with the performance of this Agreement. 

 

	 	(e)	Jingfeng agrees that in the event that any of the covenants contained in this Section 3.7 are not complied with in accordance with their terms, Carbylan shall have the right, at its sole discretion, to terminate
this Agreement immediately upon written notice to Jingfeng. Jingfeng also agrees that any breach by it of any provision of this Section 3.7 shall entitle Carbylan to injunctive and other equitable relief to secure the enforcement of these
provisions, in addition to any other remedies 

  
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 8 

	 	
(including damages) which may be available to Carbylan. 

  

	 	(f)	Jingfeng agrees to reasonably cooperate with Carbylan with respect to any investigation or audit relating to the performance of this Agreement and the FCPA, U.S. Export Control Laws or any other Anti-Corruption Law in
the Territory. 

  

	4.	Carbylan’s Assistance. 

  

	 	4.1	Transition Assistance Plan. Within [*] after the Effective Date, the Parties shall agree upon a transition assistance plan (the “Transition Assistance Plan”) pursuant to which Carbylan will provide to
Jingfeng, [*], Know-How (including documentation and/or samples) in Carbylan’s possession and Control that is necessary or reasonably useful for Jingfeng’s manufacture, development and/or commercialization of the Licensed Products under
the Development Plan. Such Transition Assistance Plan shall be consistent with the scope of Carbylan’s transition assistance outlined on Appendix V (the “Scope of Carbylan Transition Assistance”). 

 

	 	4.2	Additional Testing or Studies. Notwithstanding the foregoing, Carbylan’s assistance to Jingfeng above shall not include the conduct of any additional testing, performance studies, preclinical or clinical
study (including biocompatibility studies). In the event any applicable regulatory authority in the Territory requires any such additional testing, performance studies, preclinical or clinical studies, Jingfeng shall conduct such studies or clinical
trials in the Territory [*] unless the Parties agree in writing to the terms and conditions (including a budget) to have Carbylan perform such additional testing or studies [*]. 

 

	 	4.3	Manufacturing Know-How and Reference Samples. To the extent set forth in the Transition Assistance Plan, Carbylan shall provide Jingfeng with Know-How necessary or reasonably useful for Jingfeng to manufacture
Compound and Licensed Product. 

  

	 	4.4	Professional and Technical Support. In order to ensure the development of the Licensed Products, including any Regulatory Approval, is consistent with Carbylan’s protocols and quality control systems and
procedures as in effect from time to time, Carbylan agrees to: 

  

	 	(a)	provide reasonable professional and technical support, training and assistance, [*], to Jingfeng’s personnel at Carbylan’s facilities in the United States as requested by Jingfeng from time to time to develop
proficiency in the research, investigation and development of the Licensed Technology (to the extent consistent with the Development Plan) and the commercialization and manufacture of the Licensed Products; and [*], arrange for its professional and
technical personnel to train Jingfeng’s personnel at Jingfeng’s facilities in China in basic research, lab design and construction, clinical trials design, processing and revision, quality control, product samples, GMPs, and all other
areas as may be required to support the research, investigation, development, Regulatory Approval and commercialization of the Licensed Products in the Territory until the necessary regulatory approvals have been obtained to manufacture and sell the
Licensed Products in the Territory.

  

	 	(b)	In connection with such support, training and assistance provided by Carbylan pursuant to this Section 4.4, [*] shall be responsible for the 

 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

	 	

  
 9 

	 	
costs of all such assistance, including travel and accommodations relating to (i) such of its representatives that travel to Carbylan facilities in California for meetings with
Carbylan’s representatives and (ii) such of Carbylan’s representatives that travel to Jingfeng’s facilities in China from time to time during the Term of the Agreement. All such expenses of travel and accommodations shall be
approved in writing by [*] in advance and shall be [*] in amounts equivalent to what would have been permitted under [*] normal and customary travel policy or as otherwise agreed to by the parties. Any amounts incurred by representatives of Carbylan
in excess of amounts that would be paid under [*] travel policy shall be for the account of [*]. 

  

	 	4.5	Import and Export Licenses. Carbylan agrees to reasonably assist Jingfeng, [*], to obtain any and all import, export, re-export and other authorizations and licenses that may from time to time be required by any
governmental authority or agency in the Territory with respect to rights and licenses granted to Jingfeng under this Agreement in connection with the Licensed Technology and Licensed Products. 

 

	 	4.6	Sales and Marketing Materials. Carbylan shall use its reasonable commercial efforts to provide Jingfeng, [*], with any additional assistance reasonably requested by Jingfeng, from time to time, in producing
technical, sales, advertising and other marketing reports and information for Jingfeng which Jingfeng reasonably believes might be useful in marketing and selling the Licensed Products. 

 

	5.	License Fees and Milestone Payments 

  

	 	5.1	Up-front License Fee. In consideration of the licenses granted by Carbylan to Jingfeng herein, Jingfeng agrees to make a non-refundable up-front payment of U.S.$2.0 million no later than ten (10) Business
Days after the Effective Date to such account as shall be designated in writing by Carbylan on the Effective Date. Prior to or promptly upon execution of this Agreement, Carbylan shall provide to Jingfeng a copy of its Certificate of Incorporation,
as amended to the Effective Date, it being understood that such documents shall be required in order for approval by PRC authorities for the transfer by Jingfeng of the up-front payment to Carbylan hereunder. 

 

	 	5.2	Regulatory and Development Milestone Payments for the Licensed Product. Jingfeng agrees to make the following payments in U.S. dollars to Carbylan within [*] of the regulatory and development events set forth
below: 

  

	 	(a)	Upon the successful production by Jingfeng of the first batch of the Licensed Product that meets the product specifications used for the COR 1.0 Carbylan clinical study (see Appendix IV) [*]; 

 

	 	(b)	Upon receipt by Jingfeng of written approval of the PRC State Food and Drug Administration (“SFDA”) to commence the Phase I trial, [*]; 

 

	 	(c)	Upon the first human dosing in a Phase III trial for the Licensed Product by Carbylan in the United States, [*]; 

  

	 	(d)	Upon Carbylan obtaining regulatory approval for marketing and sale of the Licensed Product in the United States, [*]; and 

  

	 	(e)	Upon PRC SFDA approval for marketing and sale of the Licensed Product in the PRC, [*]. 

  

 

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 10 

	 	
For the avoidance of doubt, upon the achievement of each of the foregoing milestones, the applicable Party shall provide notice (the “Development Event Notice”) to the other Party
within [*] of the event. 

  

	 	5.3	Commercial Milestone Payments for the Licensed Product. Jingfeng agrees to make each of the following payments in U.S. dollars to Carbylan within [*] of achieving the following aggregate lifetime Gross Sales
Proceeds in the Territory: 

  

	 	(a)	Gross Sales Proceeds up to [*]; 

  

	 	(b)	Gross Sales Proceeds of [*]; 

  

	 	(c)	Gross Sales Proceeds of [*]; 

  

	 	(d)	Gross Sales Proceeds of [*]; 

 For the avoidance of doubt, the total payments to be made under
Section 5.3 upon achieving aggregate lifetime Gross Sales Proceeds of [*] shall be the U.S. dollar equivalent of RMB 32 million and no payments shall be due or shall otherwise accrue for aggregate lifetime Gross Sales Proceeds [*]. 

 

	 	5.4	Reduction to Future Commercial Milestone Payments. Upon the later of (i) the [*], Jingfeng’s future obligation to make the Commercial Milestone Payments set forth in Section 5.3 above shall be [*]
for all unachieved milestones. 

  

	 	5.5	Calculation of Aggregate Lifetime Gross Sales Proceeds. Sales between or among Jingfeng, its Affiliates and Sublicensees shall not be subject to or otherwise included in the calculation of aggregate lifetime
Gross Sales Proceeds for purposes of the Commercial Milestone Payments set forth in Section 5.3. All Gross Sales Proceeds shall be calculated on sales by Jingfeng, its Affiliates or Sublicensees of the Licensed Products to a Third Party.

  

	 	5.6	Financial Audit. For [*] following the final payment made to Carbylan pursuant to the terms of this Agreement, Jingfeng, its Affiliates and Sublicensees agree to keep or cause to be kept accurate records or books
of account in accordance with applicable international financial reporting standards, Chinese GAAP or such other generally accepted accounting principles as may be used by Jingfeng in preparing its external financial statements showing the
information which is necessary for the accurate determination of the Commercial Milestone Payments due hereunder. Jingfeng further agrees to permit a certified public accountant or a person possessing similar professional status and associated
with an independent accounting firm selected by Carbylan and reasonably acceptable to the Parties to inspect during regular business hours, upon [*] prior notice, and no more than [*], all or any part of Jingfeng’s records and books necessary
to check the accuracy of the aggregate lifetime Gross Sales Proceeds upon which the Commercial Milestone Payments are based. The charges of the independent accounting firm shall be paid by Carbylan; except if the Commercial Milestone Payments
have been understated by more than [*], the charges shall be paid by Jingfeng. 

  

	 	5.7	Payments. All payments set forth in this Section 5 shall be subject to receipt by Jingfeng of a written invoice from Carbylan; provided that Jingfeng shall provide Carbylan with written notice of achievement
of any milestone by Jingfeng within [*] of achieving such milestone. Jingfeng shall remit the funds to Carbylan, subject to any taxes or withholding required in accordance with Section 5.9, by wire transfer in immediately available funds to the
following bank account of Carbylan: 

  
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 11 

	
	 Bank Account:

	 Bank Name:      Silicon Valley Bank

	 Bank Address:  3003 Tasman Drive,Santa Clara, CA 95054,USA

	 Account Name:  Carbylan Biosurgery, Inc.

	 Routing & Transit No.: [*]

	 SWIFT Code:                [*]

	 Account No.:             [*]

 Notwithstanding any provision herein to the contrary, the Parties agree that, to the extent any payment required by
this Article 5 is not timely made by Jingfeng as a result of a delay in Jingfeng’s receipt of applicable regulatory approval within the Territory for the transfer of monies to Carbylan (SAFE Approval), Jingfeng shall not be deemed in default
hereunder, provided that (a) Jingfeng promptly submits a request to the appropriate authorities in the PRC for such approval and provides evidence thereof to Carbylan upon the occurrence of the event trigger of such payment; and
(b) Jingfeng promptly submits such payment to Carbylan after receiving such approval (and in the event such payment is delayed due to the delay in obtaining such approval, Jingfeng shall submit such payment within [*] after receiving such
approval). 
  

	 	5.8	Currency and Interest. All payments required under this Section 5 shall be made in U.S. dollars. For purposes of converting Chinese RMB, or other currencies applicable to the Territory, directly into U.S.
dollars, the Parties shall use the average of the exchange rate for current transactions as reported in the Wall Street Journal or Bloomberg for the five Business Days prior to the day upon which the obligation to make a payment under
Section 5.3 arose. Any payment under this Section 5 not paid on or before the specified due date shall bear interest, to the extent permitted by applicable law, at the rate of [*] per month on the unpaid balance, calculated on the number
of days such payment is delinquent. 

  

	 	5.9	Taxes. The payments to be made hereunder by Jingfeng to Carbylan shall be net payments, i.e. without deduction of any bank or transfer charges. Carbylan shall be solely responsible for and pay any and all
taxes levied on account of, or measured exclusively by, all payments it receives under this Agreement. Jingfeng shall be entitled to deduct and withhold from the relevant payments due and payable pursuant to this Agreement such amounts that
Jingfeng is required to deduct and withhold with respect to the making of such payment pursuant to the tax laws of any PRC, U.S. or foreign jurisdiction or taxing authority. To the extent that amounts are so deducted and withheld by Jingfeng, such
amounts shall be treated for all purposes of this Agreement as having been paid to Carbylan by Jingfeng. In the event such deductions or withholdings are required by applicable law, Jingfeng shall promptly deliver to Carbylan an official receipt for
taxes withheld (or other documents necessary) for Carbylan to claim a foreign tax credit (if applicable) as may be reasonably requested by Carbylan and shall provide Carbylan with reasonable assistance at Carbylan’s request. Jingfeng agrees to
take such reasonable and lawful steps as Carbylan may request to minimize the amount of tax to which the payments to Carbylan are subject. If by law, regulation or fiscal policy of a particular country in the Territory, remittance of payment in U.S.
dollars to Carbylan is restricted or forbidden, written notice, including details of such legal restriction will be promptly provided to Carbylan, and payment shall be made by the deposit thereof in local currency to the credit of Carbylan in a
recognized banking institution designated by Carbylan. 

  

	6.	Sale of the Licensed Products; Purchases of Licensed Products from Carbylan 

  

	 	6.1	Commercial Diligence.  

  

 

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 12 

	 	(a)	Jingfeng shall use Commercially Reasonable Efforts in the promotion, marketing and sale of the Licensed Products.

  

	 	(b)	Jingfeng also agrees to make commercially reasonable investments in the Territory for the promotion, marketing and sale of the Licensed Products.

 

	 	(c)	Jingfeng may choose not to launch the Licensed Products in a country or administrative region in the Territory where, in Jingfeng’s sole opinion, the launch of Licensed Products is not commercially viable and if
Jingfeng so decides not to launch any Licensed Product in any country or administrative region in the Territory, Jingfeng shall promptly notify Carbylan of such decision. If Jingfeng does not obtain a first commercial sale of any Licensed Product in
PRC [*], then Carbylan shall have the right to terminate this Agreement pursuant to Section 12.3(b). 

  

	 	6.2	Withdrawal of Licensed Products. 

  

	 	(a)	Following the launch of the Licensed Products in any country or administrative region in the Territory, Jingfeng shall have the right to withdraw the Licensed Products from sale therein, due to scientific, technical,
regulatory and/or commercial reasons, including but not limited to adverse events of the Compound or Licensed Products, marketability of the Licensed Products or reasons related to patent coverage. Jingfeng shall promptly notify Carbylan in
writing of such determination and provide Carbylan with the pertinent information with respect thereto. Promptly following the receipt of such notice from Jingfeng, the Parties shall discuss the situation in good faith. Following such
discussion, Jingfeng may withdraw the Licensed Products from sale in such country or administrative region [upon written notice to Carbylan and may terminate this Agreement in accordance with Section 12.2. Notwithstanding anything herein to the
contrary, Jingfeng shall be entitled to withdraw the Licensed Products from sale without advance discussions with Carbylan at any time if the withdrawal is for safety reasons or the result of a mandated withdrawal. 

 

	 	(b)	In the event Jingfeng withdraws any Licensed Product from the market and as a result (i) there is no Licensed Product being commercialized or developed by Jingfeng in the PRC, (ii) there is no Licensed Product
being marketed or sold in the PRC [*], and (iii) despite the Parties’ good faith efforts, the Parties agree that there are no commercially viable Licensed Products or prospective Licensed Products available for sale in the Territory, then
either Party may terminate this Agreement in accordance with Section 12.3(c). 

  

	 	6.3	Promotional and Advertising Materials. Jingfeng agrees to put the notation of “Licensed from Carbylan Biosurgery, Inc., USA” in English and in Mandarin and/or Cantonese, as applicable, clearly and
distinctly on all packages and package inserts of, and major promotional and advertising materials for, the Licensed Products to the extent such notation is permissible in legal and regulatory aspects and is commercially reasonable. 

  

	 	6.4	Patent Marking. Jingfeng shall mark all Licensed Products offered for sale, distributed, or sold hereunder, or their containers, as required by the patent marking laws of the country of sale. 

 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 13 

	 	6.5	Notification of Launch. If and when any Licensed Products are commercialized in any country or administrative region in the Territory, Jingfeng shall promptly inform Carbylan in writing of the launching date, the
country or administrative region, the Trademark for such Licensed Products, the name of the manufacturer and distributor (in each case, if other than Jingfeng), and other items reasonably requested by Carbylan.  

 

	7.	Inventions and Improvements 

  

	 	7.1	Sole Inventions. Inventions and/or improvements which are made and which relate to the Compounds and/or Licensed Products (“Inventions”) shall be owned by the Party solely making such
Invention. Each Party shall have the right to file, prosecute and maintain patent applications and patents covering Inventions made solely by that Party. 

  

	 	7.2	Joint Inventions. If an Invention is made jointly by the Parties, Jingfeng will own all results, patents and patent applications claiming such Inventions in the Territory and Carbylan will own all results,
patents and patent applications claiming such Inventions outside the Territory. Neither Party shall file any patent application(s) containing such joint Invention and/or any information or data received from the other Party without the prior written
consent of the Party providing the information or data. 

  

	 	7.3	Grant-Back License. Jingfeng hereby grants Carbylan an irrevocable, perpetual, exclusive, royalty-free license under Jingfeng’s solely-owned Inventions to make, use, develop, manufacture and commercialize
Licensed Products in the Field outside the Territory, provided that such license shall be non-exclusive (i) to the extent required by any applicable antitrust laws, in which case Jingfeng agrees that it will not either by itself or through an
Affiliate or Sublicensee, develop, manufacture or commercialize any product containing a Compound outside the Territory, and (ii) upon the expiration of the Agreement or termination of the Agreement in accordance with Section 12.4(b).

  

	8.	Confidentiality 

  

	 	8.1	Confidentiality Obligations. Except as expressly permitted herein, during the Term of this Agreement and for a period of [*] after termination or expiration of this Agreement, Carbylan and Jingfeng shall keep all
information received from the other Party (including the information received under the NDA and the Term Sheet) (“Confidential Information”) strictly confidential and shall not disclose the same to any Third Parties without the prior
written consent of the other Party, except such Confidential Information which: 

  

	 	(a)	is or becomes publicly known through no fault of the receiving party, 

  

	 	(b)	is already known to the receiving party prior to disclosure by the disclosing party as evidenced by the business records of the receiving party, 

 

	 	(c)	is learned by the receiving party from a Third Party entitled to disclose it, 

  

	 	(d)	is required to be disclosed in order to comply with a court order, law or regulation, or required by a competent authority to be disclosed; provided that such receiving party provides the disclosing party with
reasonable prior written notice of such disclosure and reasonable assistance in obtaining a protective order or confidential treatment 

  

 

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 14 

	 	
preventing or limiting the disclosure and/or requiring that the Confidential Information so disclosed be used only for the purposes for which the law or regulation required, or for which the
order was issued, 

  

	 	(e)	is independently developed by the receiving party without the use of or reference to such Confidential Information as evidenced by the business records of the receiving party, or 

 

	 	(f)	is disclosed by Jingfeng as necessary for supporting the promotional claims for the Licensed Products as pre-approved by Carbylan. 

Notwithstanding the foregoing, either Party may disclose necessary Confidential Information to its Affiliates, Sublicensees, distributors, agents,
independent contractors, investors, and financial institutions or lenders (collectively, “Authorized Persons”); provided that such Authorized Persons are under confidentiality obligations substantially equivalent to those undertaken by
such Party hereunder. Furthermore, except as required by law, regulation or court order (including for the purpose of compliance with any disclosure requirements of the U.S. Securities and Exchange Commission or the like), Carbylan shall not publish
any Know-How without the consent of Jingfeng, such consent not to be unreasonably withheld. If such consent is required, Jingfeng shall respond to any such request from Carbylan within [*] following the receipt of such request. Jingfeng shall
not publish any Know-How without the consent of Carbylan, except as may be required to comply with Applicable Law. It is recognized by the Parties that it may be advantageous for Jingfeng’s development activities for certain Know-How to be
published, and the Parties will cooperate in good faith to ensure the timely publication of appropriate Know-How in an agreed upon manner. 
  

	 	8.2	Confidential Information. The Parties agree that the terms and conditions of this Agreement shall be deemed Confidential Information of each Party. Additionally, any data and/or information received from the
other Party in connection with the calculation of the Gross Sales Proceeds and related Commercial Milestone Payments due hereunder shall be Confidential Information of such disclosing party and shall not be used by the receiving party for any
purpose other than checking the correctness of the report and for no other purpose whatsoever.

  

	 	8.3	Return of Confidential Information. All Confidential Information that is disclosed in a tangible form by a disclosing party to the receiving party under this Agreement (including, without limitation, documents,
writings, designs, drawings, specifications and information incorporated in computer software or held in electronic storage media) shall be returned to the disclosing party or destroyed promptly upon the termination of this Agreement, or upon
written request by the disclosing party, and shall not thereafter be retained in any form by receiving party, except as otherwise provided by this Agreement. 

  

	9.	Representations and Warranties 

  

	 	9.1	Mutual Representations and Warranties. Each Party hereby represents, warrants and covenants to the other Party that (i) it has the full right, power and authority to enter into this Agreement and there is nothing
which would prevent it from performing its obligations under the terms and conditions imposed on it hereunder; (ii) this Agreement has been duly authorized by all necessary corporate action and constitutes a valid and binding obligation on such
Party, enforceable in accordance with its terms; (iii) it is a corporation duly organized, validly existing and in good standing and is duly qualified and authorized to do business wherever the nature of its activities or properties requires
such qualification or authorization; (iv) no 

  

 

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 15 

	 	
registration with or approval of any government authority or agency in any jurisdiction is necessary for the execution, delivery or performance by it of any of the terms of this Agreement, or for
the validity and enforceability hereof, except such registrations and approvals that may be required in the Territory; and (v) no consent of any Third Party is or shall be required as a condition to the validity of this Agreement or the rights
and licenses granted to the other Party hereunder. 

  

	 	9.2	Carbylan Representations and Warranties. With respect to the Licensed Technology, Carbylan additionally represents, warrants and covenants to Jingfeng that: (i) it has full right, title and interest
in the Licensed Technology that is subject to the license grants set forth in Section 2.1, free and clear of any and all liens, mortgages, pledges, adverse claims, charges, security interests, encumbrances or other restrictions or limitations
whatsoever; (ii) it has provided full, accurate and complete disclosure to Jingfeng of all material information relating to the Licensed Technology and the Licensed Products; (iii) it has not granted and will not grant licenses or other
rights under the Patents that are in conflict with the terms and conditions of this Agreement; (iv) it has intended to and has included all Licensed Technology in the license grant under this Agreement which is necessary or reasonably useful
for the development, manufacture, sale, distribution, use, or import of the Licensed Products; (v) it is not aware of any infringement or threatened infringement of the Patents by a Third Party; (vi) the making, using and/or selling of the
Licensed Product in the Territory as of the Effective Date does not infringe any valid claim of any patent right of any Third Party and (vii) as of the Effective Date, to the best of Carbylan’s knowledge, none of the Patents are
invalid.  

  

	 	9.3	Jingfeng Representations and Warranties. Jingfeng additionally represents, warrants and covenants to Carbylan that (i) it has the full right, license and expertise, to develop and commercialize (after
obtaining Regulatory Approval) the Licensed Products as contemplated under this Agreement; and (ii) it will not, during the Term or thereafter, challenge Carbylan’s title or rights in and to the Patents in the Territory or the validity or
enforceability of Carbylan’s Patents. 

  

	10.	Indemnification 

  

	 	10.1	Indemnification by Jingfeng. Except as otherwise expressly provided herein, Jingfeng shall indemnify, defend and hold harmless Carbylan (including its Affiliates, directors, officers and employees) from and
against any and all liability, damage, loss or expense (including reasonable attorney’s fees and expenses of litigation) arising or resulting from any Third Party claims made or suits brought against Carbylan which arise or result from
(i) the development, manufacture, use, distribution, marketing, sale or promotion of the Compounds and/or Licensed Products (including product liabilities) by or under the control of Jingfeng, its Affiliates or Sublicensees in the Territory; or
(ii) the breach of any provision of this Agreement by Jingfeng, its Affiliates or Sublicensees (including representations and warranties), except to the extent such liability, damage, loss or expense arises from the intentional acts or
omissions, fraud, willful misconduct or gross negligence, of Carbylan or its Affiliates. If such claims are made or such suits are brought against Carbylan, Carbylan shall promptly notify Jingfeng of any such claim or suit and shall permit
Jingfeng, [*], to handle and control such claim or suit. Carbylan shall cooperate with Jingfeng, [*], in the defense of the claim or suit. Jingfeng shall not settle any suit without the prior written consent of Carbylan. 

 

	 	10.2	Indemnification by Carbylan. Except as otherwise expressly provided herein, Carbylan shall indemnify, defend and hold harmless Jingfeng (including its Affiliates, Sublicensees, directors, officers and employees)
from and against any and all liability, damage, loss or expense (including reasonable attorney’s fees and expenses of 

  

 

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 16 

	 	
litigation) arising or resulting from any Third Party claims made or suits brought against Jingfeng which arise or result from (i) the breach of any provision of this Agreement by Carbylan,
including Carbylan’s representations and warranties contained herein, (ii) the development, manufacture, use, distribution, marketing, sale or promotion of the Compounds and/or Licensed Products (including product liabilities) sold by
Carbylan or its Affiliates to Jingfeng, its Affiliates or Sublicensees for commercial sale in the Territory, for reasons other than the actions or omissions by Jingfeng (including its Affiliates, Sublicensees, directors, officers and employees), and
(iii) the infringement of any patent or other intellectual property rights of a Third Party (other than as a result of any formulation, ingredient, manufacturing process, or other technology that is developed, in-licensed (other than from
Carbylan) or otherwise introduced into the making, using or selling of the Compounds or Licensed Products by Jingfeng, in each case in a manner that is not employed by Carbylan outside the Territory), except to the extent such liability, damage,
loss or expense arises from the intentional acts or omissions, fraud, willful misconduct or gross negligence, of Jingfeng, its Affiliates or Sublicensees. If such claims are made or such suits are brought against Jingfeng, Jingfeng shall
promptly notify Carbylan of any such claim or suit and shall permit Carbylan, [*], to handle and control such claim or suit. Jingfeng shall cooperate with Carbylan, [*], in the defense of the claim or suit. Carbylan shall not settle any suit
which admits fault on the part of Jingfeng without Jingfeng’s prior written consent, not to be unreasonably withheld. 

  

	11.	Patents; Trademarks 

  

	 	11.1	Patent Prosecution and Maintenance. In connection with the Patents relating to the Compounds or Licensed Products, the Parties agree as follows: 

 

	 	(a)	Carbylan shall have the right to file, prosecute and maintain all patent applications and patents included in Licensed Technology (including any related proceedings such as interference proceedings and oppositions) in
the Territory, [*]; provided, however, that (i) Carbylan shall provide Jingfeng with an opportunity to review and comment on the nature and text of new or pending applications for the Patents in the Territory; and (ii) in the event that
Carbylan elects not to prosecute and/or maintain any or all such applications and patents in the Territory, Jingfeng shall have the exclusive right to undertake such prosecution and maintenance [*]. 

 

	 	(b)	Commencing with calendar year [*], at least [*] prior to the start of each calendar year during the Term, Carbylan shall provide Jingfeng with a good faith estimate (for planning purposes only) of all patent prosecution
and maintenance expenses for the Licensed Technology in the Territory for such calendar year. Carbylan shall have the right to incur up to [*] for each such calendar year without approval from Jingfeng, until the date of issuance of all Patents for
[*]. After issuance of a particular Patent, Jingfeng shall only be required to reimburse Carbylan for maintenance of such Patent (including without limitation any proceeding in connection therewith). Any expense that exceeds such limit shall be
subject to Jingfeng’s prior written approval, such approval not to be unreasonably withheld. 

  

	 	(c)	Carbylan shall keep Jingfeng informed on [*] of progress in the prosecution of all patent applications and in the maintenance or extension of patents falling within the Licensed Technology and shall furnish Jingfeng
with a copy of each patent application, patent or other document pertinent to prosecution, maintenance or extension of such 

  

 

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 17 

	 	
applications and patents. 

  

	 	(d)	Carbylan shall immediately advise Jingfeng of any certification filed under the U.S. “Drug Price Competition and Patent Term Restoration Act of 1984” (“ANDA Act”) claiming that any Patents are
invalid or claiming that the Patents will not be infringed by the manufacture, use or sale of a product for which an application under the ANDA Act is filed. 

  

	 	(e)	If Jingfeng exercises its right under Section 11.1(a) to undertake any prosecution and maintenance, then upon the reasonable request of Jingfeng, and [*], Carbylan will provide Jingfeng with reasonable
assistance relating to the applicable Patents, including allowing Jingfeng reasonable access to Carbylan’s files and documents and reasonable access to Carbylan’s personnel and legal counsel who may have possession of necessary or
reasonably useful information in order to prosecute and maintain such Patents. 

  

	 	(f)	In the event Jingfeng undertakes to file any patent application claiming a Compound or Licensed Product or the method of making or using such Compound or Licensed Product, Jingfeng shall consult with Carbylan to ensure
consistency with Carbylan’s international portfolio strategy prior to any such filing and, upon Carbylan’s request, provide Carbylan with a reasonable opportunity to review new or pending applications. 

 

	 	11.2	Third Party Infringement of Patents. 

  

	 	(a)	In the event that Jingfeng or Carbylan becomes aware of any infringement or potential infringement of any of the Patents by the manufacture, use, distribution, marketing or sale of the Compounds and/or Licensed Products
by a Third Party, Jingfeng or Carbylan shall promptly notify the other Party in writing, identifying the infringer or potential infringer and the infringement complained of and furnishing the information upon which such determination is
based. Jingfeng shall have the first right, but not the obligation, to sue such alleged infringers in the Territory. Jingfeng shall consult with Carbylan prior to initiating any such infringement suit in the Territory to ensure that the
intended course of action is not likely to adversely affect Carbylan’s position on its Patent portfolio outside the Territory or in any other country or administrative region within the Territory. 

 

	 	(b)	Upon reasonable request by Jingfeng and [*], Carbylan shall cooperate with Jingfeng and provide all reasonable information and assistance including allowing Jingfeng access to Carbylan’s files and documents and
access to Carbylan’s personnel and legal counsel who may have possession of relevant information, and if necessary to prosecute any legal action, joining in the legal action as a party. 

 

	 	(c)	[*] 

  

	 	(d)	In the event Jingfeng decides, within [*] of becoming aware of an infringement, in its sole discretion, not to take any action against a Third Party deemed to infringe the Patents, Jingfeng shall inform Carbylan in
writing and Carbylan thereafter shall be entitled to pursue an action to stop such infringement in its own name and [*]. Upon reasonable 

  

 

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 18 

	 	
request by Carbylan and [*], Jingfeng shall give Carbylan all reasonable information and assistance, and if necessary to prosecute any legal action, joining in the legal action as a
party. [*]. 

  

	 	11.3	Infringement of Third Party Intellectual Property. In the event of any actual or threatened suit against Jingfeng or its Affiliates, Sublicensees or customers alleging that the exploitation or use of the Patents
and/or Know-How hereunder infringes the patent or other intellectual property rights of a Third Party, Jingfeng shall promptly give written notice to Carbylan. Carbylan will provide to Jingfeng all reasonable assistance requested by Jingfeng to
defend or settle such suit and in particular Carbylan will promptly make available to Jingfeng, [*], all information in its possession or control which will assist Jingfeng in defending or otherwise dealing with such suit. Jingfeng shall have the
right to defend in its sole discretion such suit but shall consult with Carbylan before settling such suit. Jingfeng shall not settle the suit without obtaining prior written consent of Carbylan which consent shall not be unreasonably withheld.
Notwithstanding the foregoing, if such suit (i) arises or results from the breach of Carbylan’s representations and warranties under Section 9.2 and/or (ii) is subject to Carbylan’s indemnification obligation under
Section 10.2, then this Section 11.3 shall not apply and the defense and settlement of such suit shall be subject to Section 10.2. 

  

	 	11.4	Trademarks. 

  

	 	(a)	Jingfeng may, at its sole discretion, use its own trademarks, trade names, commercial symbols or logos for the marketing and sale of the Licensed Products in the Territory. Jingfeng may apply for one or more trademarks
in the Territory in its own name and as the exclusive owner thereof with respect to the Licensed Products, provided that Jingfeng may use trademarks, trade names, company name, logos or other marks that are the same as or similar to the Trademarks
only with Carbylan’s prior written consent and pursuant to terms and conditions of this Agreement. 

  

	 	(b)	Jingfeng shall not use or permit or authorize any Affiliate or Sublicensee to use the Trademarks as part of a corporate name or tradename without the express prior written consent of Carbylan and Jingfeng shall not
permit or authorize use of the Trademarks in such a way so as to give the impression that the Trademarks, or any modifications thereof, are the property of Jingfeng. 

 

	 	(c)	Jingfeng shall cooperate fully and in good faith with Carbylan for the purpose of securing and preserving Carbylan’s rights in and to the Trademarks, [*]. Nothing contained in this Agreement shall be construed as
an assignment or grant to Jingfeng of any right, title or interest in or to the Trademarks, it being understood that all rights relating thereto are reserved by Carbylan, except for the license hereunder to Jingfeng of the right to use the
Trademarks only as specifically and expressly provided herein. Jingfeng further agrees that Carbylan is and will continue to be the sole and exclusive owner of all rights, title and interest in and to each Trademark in any form or embodiment thereof
and agrees that all goodwill associated with or attached to the Trademark arising out of the use thereof by Jingfeng shall inure to the benefit of Carbylan. 

  

	 	(d)	Jingfeng agrees that it will not, during the Term or thereafter, attack Carbylan’s title or rights in and to the Trademarks in the Territory or the validity of Carbylan’s Trademarks. 

 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 19 

	 	(e)	The nature and quality of the Licensed Products, and all advertising and promotional uses of the Trademarks by Jingfeng, shall conform to or exceed industry standards for products similar to the Licensed Products.

  

	 	(f)	Jingfeng agrees to comply with all Applicable Laws pertaining to the proper use and designation of the Trademarks. 

  

	12.	Term and Termination 

  

	 	12.1	Term. This Agreement shall become effective as of the Effective Date and expires upon the later of the date of the expiration of the last Patent or the invalidation of the last Patent (the “Term”).
After expiration of this Agreement pursuant to this Section 12.1, Jingfeng’s license shall be considered fully paid and become non-exclusive, and Jingfeng and its Affiliates and Sublicensees shall be allowed to continue using all Know-How
for the manufacture, sale or use of the Compounds and/or Licensed Products in the Territory with no further consideration to Carbylan. 

  

	 	12.2	Termination by Jingfeng. Jingfeng may terminate this Agreement upon [*] prior written notice if the conditions set forth under Section 6.2(a) are met. 

 

	 	12.3	Termination by Either Party. This Agreement shall be terminable by either Party at any time, upon the occurrence of any of the following events: 

 

	 	(a)	Should the other Party hereto become insolvent, or if proceedings in voluntary or involuntary bankruptcy or pursuant to any other insolvency law shall be instituted by, on behalf of or against the other Party, or if a
trustee or receiver of the Party’s property shall be appointed; or 

  

	 	(b)	If the other Party commits any material breach of any of the terms of this Agreement (and in the case of Jingfeng, including its obligations under Section 3.4(b) and/or Section 6.1(c)); and (a) fails to
remedy such breach within [*] after written notice thereof has been given by the non-breaching Party, or (b) in the event that such breach is not capable of cure within such [*] period, fails to commence to cure such breach within such period
and thereafter to prosecute such cure diligently to completion; provided, however, that in no event shall the period for such cure be greater than [*] after the non-breaching Party’s notice of such breach; or 

 

	 	(c)	If the conditions under Section 6.2(b) are satisfied, either Party may terminate this Agreement by providing [*] prior written notice to the other Party. 

 

	 	(d)	The termination of this Agreement shall not relieve the Parties from performing any obligations accrued prior to the date of this Agreement terminates. 

 

	 	12.4	Effect of Termination. 

  

	 	(a)	Upon termination of this Agreement in whole or in part pursuant to Section 12.2 or 12.3, Jingfeng shall promptly return all applicable Know-How supplied from Carbylan and cease any terminated activities hereunder
(including without limitation development, manufacture, use and/or sale of the Compounds and the Licensed Products); provided however, that Jingfeng, its Affiliates and Sublicensees shall have the 

 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 20 

	 	
right, if applicable, to sell any remaining Compounds or Licensed Products made prior to said termination and shall pay to Carbylan any Commercial Milestone Payments owed to Carbylan with respect
to such sales.

  

	 	(b)	Except in the event of a termination of this Agreement by Jingfeng pursuant to Section 12.3(a) or (b), (i) Jingfeng shall transmit, without charge, to Carbylan applicable registration data generated by
Jingfeng up to the date of early termination without delay; (ii) upon Carbylan’s request, Jingfeng shall grant or cause to be granted to Carbylan a worldwide non-exclusive license, with the right to sublicense to any Third Party, to
manufacture, use and sell the Compounds and Licensed Products in the Field under any patent rights held or controlled by Jingfeng, its Affiliates or Sublicensees which cover the development, manufacture, use and/or sale of the Compounds and the
Licensed Products, and utilizing Jingfeng’s registration data (including that of its Affiliates and/or Sublicensees) generated up to the date of early termination on the terms and conditions mutually agreed upon by the Parties; and
(iii) if the Regulatory Approval of any Licensed Product is already held by Jingfeng, its Affiliates and/or Sublicensees at the date of such early termination of this Agreement, Jingfeng shall take all reasonable steps to transfer or cause to
be transferred, without charge, such Regulatory Approval to Carbylan. 

  

	 	12.5	Survival. Termination or expiration of this Agreement for any reason shall be without prejudice to any rights that shall have accrued to the benefit of any Party prior to such termination, relinquishment or
expiration including the payment obligations hereunder and any and all damages or remedies arising from any breach hereunder. Such termination, relinquishment or expiration shall not relieve any Party from obligations which are expressly indicated
to survive termination of this Agreement. The provisions of Sections 7.3, 8.1, 8.2, 8.3, 10.1, 10.2, 12.4, 12.5, 13.2, and 13.3 shall survive the expiration or termination of this Agreement for any reason. 

 

	13.	Miscellaneous 

  

	 	13.1	Assignment. This Agreement may not be assigned by either Party, without the prior written consent of the other Party. Notwithstanding this Section 13.1, Carbylan may assign this Agreement,
without consent, to an Affiliate or to a successor in interest pursuant to a corporate reorganization, consolidation, merger, acquisition, change of control with respect to its outstanding stock, sale of substantially all of its assets, or similar
transaction. Carbylan shall provide Jingfeng with prior written notice of any such assignment; provided, that Carbylan may provide such written notice promptly upon such assignment if such advance notice is not permitted by such Third Party.
Notwithstanding this Section 13.1, Jingfeng shall be entitled to perform its obligations and rights under this Agreement through an Affiliate or a Third Party, and shall be entitled to grant appropriate contracts under this Agreement to
Affiliates and Third Parties accordingly. Jingfeng shall ensure that such Affiliates and Third Parties will comply with the provisions of this Agreement. This Agreement shall be binding upon and inure to the benefit of the successors and
assignees of the Parties hereto. The Parties acknowledge and agree that if any person, entity, company or organization acquires or merges with Carbylan after the Effective Date or becomes an Affiliate of Carbylan by reason of a merger, acquisition,
change of control or similar transaction after the Effective Date, then (a) all intellectual property and know-how owned or controlled by such entity (i) prior to the closing of such transaction or (ii) after such closing to the
extent such intellectual property or know-how is developed and/or commercialized by such entity thereafter in an independent program without a 

  
 21 

	 	
license from Carbylan or without the use of the Licensed Technology, shall be excluded from the scope and terms of this Agreement and for clarity shall not be included in the scope of the license
granted pursuant to Section 2.1; and (b) Section 2.4 shall not apply to such entity with respect to any product development, manufacture or commercialization by such entity (i) prior to the closing of such transaction or
(ii) after such closing if such product is not covered by, or does not otherwise infringe, any Patent in the Territory. 

  

	 	13.2	Governing Law. This Agreement shall be governed by and construed solely in accordance with the laws of Delaware, without regard to conflicts of law principles. 

 

	 	13.3	Arbitration. The Parties hereto shall use their best efforts to settle amicably any controversies arising out of this Agreement. Any controversy or disputes or claims arising between the Parties in
connection with this Agreement which cannot be settled in an amicable way shall be finally settled under the Rules of Arbitration of the International Chamber of Commerce (the “Rules”), by one or more arbitrators appointed in accordance
with the said Rules. Proceedings shall be conducted in the English language. Any award or decision made in such arbitration shall be final and binding upon the Parties and enforceable in a court of competent jurisdiction. The
arbitration shall be held in Hong Kong. 

  

	 	13.4	Force Majeure. All cases of force majeure, i.e. any events beyond the reasonable control of the Parties due to fire, flood, earthquake, explosion, riot, strike, lockout, war and similar casualties, shall, for the
duration and to the extent caused by such disturbances, release the affected Party from the performance of its obligations hereunder. Either Party shall notify the other Party promptly in the event of any indications of any such incidents
occurring and shall discuss the effect of such incidents on this Agreement and the measures to be taken. Either Party shall use its best endeavors to reasonably avoid or restrict any detrimental effects in connection with such incidents.

  

	 	13.5	Waiver. No waiver by one Party in one or more instances of any of the provisions of this Agreement or the breach thereof by the other Party shall establish a precedent for any other instance or with respect to
any other provision. 

  

	 	13.6	Notice. Any notice or other communication required or permitted under this Agreement shall be in writing, in English and shall be deemed to have been duly given, when received, if hand-delivered or sent by
facsimile later confirmed in writing or, three (3) days after depositing, if placed in the mail for delivery by registered or certified mail, return receipt requested, postage prepaid and addressed to the appropriate Party at the following
addresses: 

 For Carbylan: 

Carbylan Biosurgery, Inc. 
 Attention: Chief
Financial Officer or his/her assignee 
 3181 Porter Drive 

Palo Alto, CA 94304 
 USA 

Facsimile: 650-855-9119 
 For Jingfeng: 

Shanghai Jingfeng Pharmaceutical Co, Ltd. 

No. 50, Luoxin Road 
 Baoshan District,
Shanghai, PRC, 201908 
 Attn.: Fu Ailing 

Facsimile: +86-21-583-60818 

  
 22 

	 	13.7	Severability. If any provision of this Agreement is found to be illegal or invalid for any reason, the remaining provisions shall be construed and applied so as to most closely legitimately effectuate its
intent. The invalidity or non-enforceability of one Article or any part of an Article of this Agreement in any jurisdiction shall not cause the invalidity of the whole Agreement as to such jurisdiction, and shall not affect the validity or
enforceability of such Article or part of an Article in any other jurisdiction. 

  

	 	13.8	Headings. The headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. 

 

	 	13.9	Publicity. Neither Party shall make a public announcement regarding the fact of conclusion of this Agreement without the prior written consent of the other Party. When one Party wishes to make a public
announcement regarding the Agreement, such Party shall notify the other Party of its intended announcement text and other relevant information on which the other Party may comment. 

 

	 	13.10	Entire Agreement; Amendment. This Agreement including the Appendices attached hereto and made a part hereof embodies the entire understanding between the Parties concerning the subject matter hereof, and all
prior representations, warranties or agreements relating hereto are hereby terminated and shall be of no force or effect whatsoever. No amendment, change, modification nor alteration of the terms and conditions of this Agreement shall be
binding upon either party unless in writing and signed by the Parties. 

  

	 	13.11	Counterparts. This Agreement may be executed in one or more counterparts, all of which will be deemed an original, and will become effective when one or more counterparts have been signed by each of the Parties
and delivered to the other Party, it being understood that all Parties need not sign the same counterpart; all of such counterparts will together constitute one and the same instrument. The Parties agree that facsimile copies or AdobeTM Portable
Document Format (PDF) copies of this Agreement will be deemed to be the equivalent of originals. 

 [Remainder of Page Intentionally
Left Blank] 

  
 23 

 IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed by their respective duly
authorized officers as of the day and year first written above. 
  

							
	CARBYLAN BIOSURGERY, INC.	 		  	SHANGHAI JINGFENG PHARMACEUTICAL CO., LTD.	  	
				
	 By: /s/ George Y. Daniloff
	 		  	 By: /s/ Xiangwu Ye
	  	
				
	Name: George Y. Daniloff	 		  	Name: Xiangwu Ye	  	
	Title: President and CEO	 		  	Title: President and CEO	  	
	Date: November 15, 2012	 		  	Date: November 15, 2012	  	

  

					
	Appendix I -	 	Patents	 	
	Appendix II -	 	Trademarks	 	
	Appendix III -	 	FCPA Guidelines	 	
	Appendix IV -	 	COR 1.0 Hydros-TA Product Release Specifications	 	
	Appendix V -	 	Scope of Carbylan Transition Assistance	 	

  
 24 

 Appendix I 

Patents 
  

 

					
	Country	 	Patent No. or Application No.	  	Invention Title
	PCT	 	PCT/US10/043108	  	MODIFIED HYALURONIC ACID POLYMER COMPOSITIONS AND RELATED METHODS
	PCT	 	PCT/US2012/034133	  	IN-SITU GEL FORMING COMPOSITIONS
	CN	 	201080044014.3	  	MODIFIED HYALURONIC ACID POLYMER COMPOSITIONS AND RELATED METHODS
	HK	 	To be filed before 8 December 2012	  	MODIFIED HYALURONIC ACID POLYMER COMPOSITIONS AND RELATED METHODS

  
 25 

 Appendix II 

Trademarks 
 None. 

  
 26 

 Appendix III 

FCPA Guidelines 
 Jingfeng understands and
acknowledges that the obligations hereunder are in addition to, without prejudice to, not in lieu of, any of its obligations under Section 3.7 of the Agreement. 

Ø Compliance with FCPA. A summary of the FCPA
and related information can be found at http://www.justice.gov/criminal/fraud/fcpa. By signing this Agreement, Jingfeng warrants that: 
 ¡ It is familiar with the provisions and restrictions contained in the OECD Convention and FCPA. 

¡ It shall comply with the FCPA in marketing,
selling and/or servicing Licensed Products under this Agreement. 

¡ It shall not, in the course of its duties under
the Agreement, offer, promise, give, demand, seek or accept, directly or indirectly, any gift or payment, consideration or benefit in kind that would or could be construed as an illegal or corrupt practice. 

¡ It is not a government official (as the term is
defined in the FCPA) or affiliated with any government official. 

¡ It shall immediately notify Carbylan of any
attempt by a government official to directly or indirectly solicit, ask for, or attempt to extort anything of value from Jingfeng, and shall refuse any such solicitation, request or extortionate demand. 

Ø Compliance Certificate. From time to time upon
request from Carbylan, Jingfeng shall submit a compliance certificate in the form set forth at the end of this Appendix III stating that (i) it fully understands its obligations under this Appendix III and any other applicable
laws and regulations mentioned herein or as may come into existence from time to time after the Signing Date; (ii) it has been complying with this Appendix III and any other applicable laws and regulations mentioned herein or as may come
into existence from time to time after the Signing Date; and (iii) it will continue to comply with this Appendix III and any other applicable laws and regulations mentioned herein or as may come into existence from time to time after the
Signing Date. 
 Ø No Action. In no event
shall Carbylan be obligated under the Agreement to take any action or/ omit to take any action that Carbylan believes, in good faith, would cause it to be in violation of any applicable laws and regulations, including the anti-bribery laws
referenced in this Appendix III. 
 Ø Due
Diligence. Carbylan has the right to visit the offices of Jingfeng from time to time during the term of the Agreement on an “as needed” basis and conduct due diligence in relation to Jingfeng’s business related to performance of
its obligations under this Appendix III and may do so in the way it deems necessary, appropriate or desirable so as to ensure that Jingfeng complies with this Appendix III and any other applicable laws and regulations in its business
operations. Jingfeng shall make every effort to cooperate fully with Carbylan in any such due diligence. 
 Ø Audit. In the event that Carbylan has commercially reasonable evidence to believe that a breach of any obligation of Jingfeng under this Appendix III has occurred or is imminent,
Carbylan shall have the right to request in writing adequate assurances that Jingfeng is in compliance with its obligations under this Appendix III. In the event Jingfeng is unable or unwilling to provide commercially reasonable assurances
within [*] of such request, Carbylan shall have the right to select an independent third party to conduct an audit of Jingfeng and review relevant books and records of Jingfeng to satisfy itself that no breach has occurred. Unless otherwise required
under applicable laws and regulations or by order of a competent court or regulatory authority, Carbylan shall ensure that the selected independent third party will keep confidential all audited matters and the results of the audit. To the extent
Carbylan has 
  
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 27 

 
commercially reasonable evidence to believe that a breach of any obligation of Jingfeng under this Appendix III has occurred, Carbylan reserves the right to the extent required by law to disclose
to the U.S. or Chinese government, its agencies and/or any other government or non-government party, such evidence of the violation by Jingfeng of any applicable law, including a violation of the FCPA or any other applicable anti-bribery law. 

Ø Material Breach. Jingfeng acknowledges that
any violation of this Appendix III by Jingfeng or any of its Affiliates, sublicensees or subcontractors shall be deemed a material breach of this Agreement by Jingfeng and shall give rise to the right for Carbylan to terminate this Agreement. 

  
 28 

 CERTIFICATE OF COMPLIANCE 

I,                     
                                        
of Jingfeng Pharmaceutical Co., Ltd., which is conducting business with Carbylan per our agreement dated
                                    . 

I hereby acknowledge and certify that I am familiar and knowledgeable about the requirements of the Foreign Corrupt Practices Act (“FCPA”) and other
applicable anti-corruption laws and their requirements. 
 I certify that I have not, and will not, take any action in furtherance of an unlawful offer, promise, or
payment to a foreign official that would cause Carbylan to be in violation of the FCPA, any other applicable anti-corruption law. I further certify that I have made no agreement or commitment, directly or indirectly, which, if carried out in the
future, would be in violation of the FCPA or any other applicable anti-corruption law. 
  

					
	Signature:	 	  
	 	
			
	Printed Name:	 	  
	 	
			
	Title:	 	  
	 	
			
	Company:	 	  
	 	
			
	Dated:	 	  
	 	

  
 29 

 Appendix IV 

COR 1.0 Hydros-TA Product Release Specifications 

Certificate of Analysis 

Hydros TA Joint Therapy 
  

			
	Part Number 9650	  	
	Lot Number XXXXXX 	  	Batch Size xxxx units
	Expiration Date MM/YYYY 	  	Date of Manufacture dd/mmm/yy

  
  

							
	 	 	 	 
	
Parameter
  
	  	 Method

 
	 	 Acceptance Criteria

 
	  	 Results

 

	[*]	  	Visual Inspection	 	 [*]

 
	  	 
	[*]	  	Visual Inspection	 	 – [*];

– [*]
  
	  	 
	[*]	  	RTM010	 	 [*]

 
	  	 
	[*]	  	RTM010	 	 [*]

 
	  	 
	[*]	  	RTM010	 	 [*]

 
	  	 
	[*]	  	RTM016	 	 [*]

 
 [*]
  
	  	 
	[*]	  	RTM016	 	 [*]

 
	  	 
	[*]	  	Provided by CMO	 	 [*]

 
	  	 
	[*]	  	Provided by CMO	 	 [*]

 
	  	 

 This product was manufactured in such a way that it is in compliance with Domestic and International Good Manufacturing
Practices, as applicable. 
 Released
By:                                        
                   Release Date:                 

 
  

	[*]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

  
 30 

 Appendix V 

Indicative Scope of Carbylan Transition Assistance 

Carbylan to register an executed copy of the Agreement with SIPO, as requested by Jingfeng (for both the pending CN patent application, and the second CN patent
application to be filed under the second PCT/US application). 
 Establish Development Plan 

	 	•	 	Transfer initial documentation to Jingfeng 

	 	¡ 	 	Send copy of FDA Pre-IND meeting package (As soon as possible after the Effective Date) 

¡   Summary and
description of the product, manufacturing, preclinical and COR 1.0 clinical studies 
 ¡   Allows Jingfeng to review product and develop an initial list of specific questions and documentation that they would like to be transferred 

	 	¡ 	 	Send documents on initial list (Dec 2012) 

	 	•	 	Carbylan/Jingfeng Technology Transfer Summit (Dec 2012) 

	 	¡ 	 	Carbylan will present an overview of the Hydros-TA product and answer initial questions from Jingfeng 

	 	¡ 	 	Carbylan/Jingfeng finalize an initial development plan to submit SFDA phase 1 study application 

	 	•	 	Approve initial development plan (Dec 2012) 

 Hands-On Technology Transfer (Product Manufacture)

	 	•	 	Appropriate documents transferred to Jingfeng and Product has been reviewed at the summit 

	 	•	 	Jingfeng gains theoretical understanding of the manufacturing process 

	 	•	 	Jingfeng visits Carbylan to have a hands-on demonstration of the manufacturing process at Carbylan’s facility (TBD) 

	 	¡ 	 	Manufacture of the raw materials 

	 	¡ 	 	Manufacture of Hydros-TA 

	 	•	 	Carbylan visits Jingfeng to provide guidance for manufacture of raw materials and Hydros-TA at Jingfeng’s facility (TBD) 

Other Items as Agreed Between the Parties 

  
 31

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00238-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00238-of-00352.parquet"}]]